[go: up one dir, main page]

US20050171158A1 - Melanocortin receptor ligands - Google Patents

Melanocortin receptor ligands Download PDF

Info

Publication number
US20050171158A1
US20050171158A1 US11/092,100 US9210005A US2005171158A1 US 20050171158 A1 US20050171158 A1 US 20050171158A1 US 9210005 A US9210005 A US 9210005A US 2005171158 A1 US2005171158 A1 US 2005171158A1
Authority
US
United States
Prior art keywords
cyclohexyl
piperidin
ethyl
oxo
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/092,100
Inventor
Frank Ebetino
Xuewei Liu
Mark Solinsky
John Wos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/092,100 priority Critical patent/US20050171158A1/en
Publication of US20050171158A1 publication Critical patent/US20050171158A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Definitions

  • the present invention relates to melanocortin (MC) receptor ligands that have a 4-substituted piperidine ring, which provides for enhanced activity.
  • MC melanocortin
  • These ligands preferably exhibit selectivity for the MC-3 and/or MC-4 receptors relative to the other melanocortin receptors (in particular the MC-1 receptor) and are suitable for use in pharmaceutical compositions and in treatment methods.
  • Melanocortin peptides are natural peptide hormones in animals and man that bind to and stimulate MC receptors.
  • melanocortins are ⁇ -MSH (melanocyte stimulating hormone), ⁇ -MSH; ⁇ -MSH, ACTH (adrenocorticotropic hormone) and their peptide fragments.
  • MSH is mainly known for its ability to regulate peripheral pigmentation, whereas ACTH is known to induce steroidoneogenesis.
  • the melanocortin peptides also mediate a number of other physiological effects.
  • Both the MC-4 and MC-3 receptors have been localized to the hypothalamus, a region of the brain believed to be involved in the modulation of feeding behavior.
  • Compounds showing selectivity for the MC-3/MC-4 receptors have been shown to alter food intake following intracerebroventricular and peripheral injection in rodents. Specifically, agonists have been shown to reduce feeding, while antagonists have been shown to increase feeding.
  • the role of the MC-4 and MC-3 receptors have been defined in the control of body weight regulation in mammals. It is believed that the MC-3 receptor influences feed efficiency and the partitioning of fuel stores into fat, whereas the MC-4 receptor regulates food intake and possibly energy expenditure. Thus, these receptor subtypes appear to reduce body weight through distinct and complementary pathways. Therefore compounds that stimulate both the MC-3 and MC-4 receptors may have a greater weight loss effect than those that are selective for either the MC-3 or MC-4 receptor.
  • Body weight disorders such as obesity, anorexia and cachexia are widely recognized as significant public health issues and there is a need for compounds and pharmaceutical compositions which can treat these disorders.
  • the Applicants have discovered a class of compounds that surprisingly have high affinity for the MC-4 and/or the MC-3 receptor subtypes, and that are typically selective for these MC receptors relative to the other melanocortin receptor subtypes, particularly the MC-1 subtype.
  • the present invention relates to the surprising discovery that certain 4,4-disubstituted piperidines are affective as melanocortin receptor ligands.
  • the compounds including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R is a substituted or unsubstituted hydrocarbyl unit selected from the group consisting of:
  • the present invention relates to melanocortin (MC) receptor ligands.
  • the melanocortin (MC) class of peptides mediates a wide range of physiological effects.
  • Synthetic peptides and peptide mimetics, which modulate the interaction of natural MC ligands have varying degrees of selectivity and binding.
  • the present invention is directed to ligands that are selective for the MC4 receptor, or that are selective for both the MC4 and MC3 receptor while minimizing the interaction at the MC1, MC2, and MC5 receptors.
  • hydrocarbyl is defined herein as any organic unit or moiety which is comprised of carbon atoms and hydrogen atoms. Included within the term hydrocarbyl are the heterocycles which are described herein below. Examples of various unsubstituted non-heterocyclic hydrocarbyl units include pentyl, 3-ethyloctanyl, 1,3-dimethylphenyl, cyclohexyl, cis-3-hexyl, 7,7-dimethylbicyclo[2.2.1]-heptan-1-yl, and naphth-2-yl.
  • hydrocarbyl is the aromatic (aryl) and non-aromatic carbocyclic rings, non-limiting examples of which include cyclopropyl, cyclobutanyl, cyclopentanyl, cyclohexane, cyclohexenyl, cycloheptanyl, bicyclo-[0.1.1]-butanyl, bicyclo-[0.1.2]-pentanyl, bicyclo-[0.1.3]-hexanyl (thujanyl), bicyclo-[0.2.2]-hexanyl, bicyclo-[0.1.4]-heptanyl(caranyl), bicyclo-[2.2.1]-heptanyl(norboranyl), bicyclo-[0.2.4]-octanyl(caryophyllenyl), spiropentanyl, diclyclopentanespiranyl, decalinyl, phenyl, benzyl, naphthyl
  • heterocycle includes both aromatic (heteroaryl) and non-aromatic heterocyclic rings non-limiting examples of which include: pyrrolyl, 2H-pyrrolyl, 3H-pyrrolyl, pyrazolyl, 2H-imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, isoxazolyl, oxazoyl, 1,2,4-oxadiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-pyran-2-one-yl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, s-triazinyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 1,4-oxazinyl, morpholinyl, aze
  • alkylenearyl is a benzyl unit having the formula: whereas an example of a unit defined by the term “alkyleneheteroaryl” is a 2-picolyl unit having the formula:
  • arylene and heteroarylene relate to aryl and heteroaryl units which can serve as part of a linking group, for example, units having the formula: which represent an arylene and heteroarylene unit respectively.
  • substituted is used throughout the specification.
  • substituted is defined herein as “encompassing moieties or units which can replace a hydrogen atom, two hydrogen atoms, or three hydrogen atoms of a hydrocarbyl moiety.
  • substituted can include replacement of hydrogen atoms on two adjacent carbons to form a new moiety or unit.”
  • a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like.
  • a two hydrogen atom replacement includes carbonyl, oximino, and the like.
  • a two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like.
  • Three hydrogen replacement includes cyano, and the like.
  • An epoxide unit is an example of a substituted unit which requires replacement of a hydrogen atom on adjacent carbons.
  • substituted is used throughout the present specification to indicate that a hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain, can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as “substituted” any number of the hydrogen atoms may be replaced.
  • 4-hydroxyphenyl is a “substituted aromatic carbocyclic ring”
  • (N,N-dimethyl-5-amino)octanyl is a “substituted C 8 alkyl unit
  • 3-guanidinopropyl is a “substituted C 3 alkyl unit”
  • 2-carboxypyridinyl is a “substituted heteroaryl unit.”
  • Non-limiting examples include:
  • the compounds of the present invention include all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts of compounds having the core scaffold represented by the formula: wherein R is a substituted or unsubstituted hydrocarbyl unit selected from the group consisting of:
  • R units relate to substituted and non-substituted aryl units wherein R units are substituted or unsubstituted phenyl, benzyl, naphthyl, and naphthalen-2-ylmethyl.
  • a first iteration of this aspect encompasses R units which are selected from the group consisting of phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, and 4-methylphenyl.
  • R units which are selected from the group consisting of phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, and 4-methylphenyl.
  • An example of this aspect which is particularly effective in enhancing MC-4 activity is 4-chlorophenyl, especially when combined with W 1 units comprising a carbocyclic ring, for example, cyclohexyl.
  • a second iteration of this aspect encompasses R units which are selected from the group consisting of 1-naphthyl, 2-naphthyl, naphthalen-1-ylmethyl, naphthalen-2-ylmethyl, and 1-hydroxynaphthalen-2-ylmethyl.
  • R units relate to substituted and non-substituted heteroaryl units wherein R units comprise substituted or unsubstituted quinolinyl, isoquinolinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl.
  • a first iteration of this aspect encompasses R units which are 1,2,3,4-tetrahydroisoquinolinyl and 1,2,3,4-tetrahydroquinolinyl.
  • a second iteration of this aspect encompasses R units which are 6-hydroxy-1,2,3,4-tetrahydroisoquinolinyl and 6-hydroxy-1,2,3,4-tetrahydroquinolinyl.
  • R relates to phenyl rings comprising a C 1 -C 4 alkyl unit, non-limiting examples of which include 4-methylphenyl, 2,4-dimethylphenyl, as well as mixed alkyl rings, inter alia, 2-methyl-4-isopropyl.
  • a yet further aspect of R relates to substituted or unsubstituted heteroaryl rings selected from the group consisting of thiophenyl, furanyl, oxazolyl, thiazolyl, pyrrolyl, and pyridinyl.
  • W is a pendant unit having the formula: -L-Q wherein Q is hydrogen or a substituted or unsubstituted unit selected from:
  • the number of rings which comprise Q are from 1 to 3.
  • Aspects described herein include the substituted and unsubstituted mono-cyclic rings, inter alia, piperidine, pyrazine, pyrrolidine, imidazole, and the like, as well as fused-ring units, inter alia, quinoline, isoquinoline, indole, and the like. Examples of the various aspects of Q are described further herein below. All units which comprise Q can be substituted or unsubstituted by the units described herein above.
  • the first aspect of Q units relates to substituted or unsubstituted fused-ring heterocyclic units comprising 5 to 12 carbon atoms.
  • Q units relates to substituted or unsubstituted fused ring heterocycles comprising one nitrogen atom, a first embodiment of which relates to quinoline or isoquinoline rings having the formula: a second embodiment relates to units having the formula: and a third embodiment relates to the tetrahydroquinoline and tetrahydroisoquinoline rings having the formula:
  • the second aspect of the present invention as it relates to Q units comprises nitrogen-atom containing six-member rings which can optionally further comprise a second nitrogen or other heteroatom, for example, the heteroaryl rings having the formulae:
  • Other units included in this aspect include: morpholinyl, piperidinyl, triazinyl, and the like.
  • the third aspect of the Q units of the present invention relates to 5-member ring nitrogen atom containing heterocycles.
  • a first iteration of the third aspect of Q relates to heterocycles selected from the group consisting of:
  • R 2 units which are selected from the group consisting of:
  • a yet other aspect of Q relates to units having the formula:
  • a first iteration of this aspect relates to Q units which are carboxylic acids.
  • a second iteration of this aspect relates to Q units which are amides, non-limiting examples of which include
  • a third iteration of this aspect relates to Q units which are substituted C 1 -C 6 linear, branched, or cyclic alkyl; non-limiting examples of which include:
  • R 3a , R 3b , R 4a , R 4b are each independently:
  • the index j is from 0 to 3 and the index k is from 0 to 3.
  • a first aspect of L relates to linking groups wherein the index w is equal to 0 and the indices j and k are each equal to 1.
  • This aspect relates to R 3a and R 3b and R 4a and R 4b units independently selected from:
  • linking groups relates to units comprising at least one unit having the formula:
  • linking units relate to L units which comprise units wherein the indices j and k are each equal to 0, the index w is 1 and T is a unit having the formula: said units relating to Category I of compounds according to the present invention.
  • W 1 is a pendant unit having the formula: —(CH 2 ) x —R 1
  • the first aspect of W 1 relates units having the formula:
  • R 1 having the formula: —R 1 wherein the index x is 0.
  • the first embodiment of this aspect relates to R 1 units which are substituted or unsubstituted carbocyclic rings selected from the group consisting of cyclopropyl, cyclopentyl, cyclohexyl, 2-methylenecyclopentyl, and cycloheptyl.
  • a second embodiment of this aspect relates to R 1 units which are aromatic or non-aromatic heterocyclic rings selected from the group consisting of thiophen-2-yl, piperidin-4-yl, pyridin-2-yl, and morpholin-4-yl.
  • the second aspect of W 1 relates to units having the formula: —CH 2 —R 1 wherein the index x is 1.
  • the first embodiment of this aspect relates to R 1 units which are substituted and unsubstituted carbocyclic rings selected from the group consisting of cyclopropyl, cyclopentyl, cyclohexyl, 2-methylenecyclopentyl, and cycloheptyl.
  • a second embodiment of this aspect relates to R 1 units which are aromatic or non-aromatic heterocyclic rings selected from the group consisting of thiophen-2-yl, piperidin-4-yl, pyridin-2-yl, and morpholin-4-yl.
  • W 2 is a pendant unit having the formula:
  • the index y is from 0 to 10.
  • W 2 units which are short chain alkyl or alkenyl(lower hydrocarbyl) esters, R 2 having the formula: —C(O)OR 6 ; in one iteration R 6 is C 1 -C 4 linear branched or cyclic alkyl or alkenyl.
  • Non-limiting examples include —C(O)OCH 3 ; —C(O)OCH 2 CH 3 ; —C(O)OCH 2 CH 2 CH 3 ; —C(O)OCH(CH 3 ) 2 ; —C(O)OCH 2 CH 2 CH 2 CH 3 ; —C(O)OCH 2 CH(CH 3 ) 2 ; —C(O)OCH 2 CH ⁇ CHCH 3 ; —C(O)OCH 2 CH 2 CH(CH 3 ) 2 ; —C(O)OCH 2 C(CH 3 ) 3 ; and the like.
  • R 2 units which are short chain substituted or non-substituted amides having the formula: —C(O)NHR 6 or —NHC(O)R 6 in one iteration
  • R 6 is C 1 -C 4 linear branched or cyclic alkyl or alkenyl.
  • Non-limiting examples include —C(O)NHCH 3 ; —C(O)NHCH 2 CH 3 ; —C(O)NHCH(CH 3 ) 2 ; —C(O)NHCH 2 CH 2 CH 3 ; —C(O)NHCH 2 CH 2 CH 2 CH 3 ; —C(O)NHCH 2 CH(CH 3 ) 2 ; —C(O)NH 2 ; —C(O)NHCH 2 CH ⁇ CHCH 3 ; —C(O)NHCH 2 CH 2 CH(CH 3 ) 2 ; —C(O)NHCH 2 C(CH 3 ) 3 ; —C(O)NHCH 2 CH 2 SCH 3 ; —C(O)NHCH 2 CH 2 OH; —NHC(O)CH 3 ; —NHC(O)CH 2 CH 3 ; —NHC(O)—CH 2 CH 2 CH 3 ; and the like.
  • W 2 units encompasses units having the formula: —(CH 2 ) y —R 2 wherein the index y is from 1 to 3.
  • a first iteration of this aspect relates to R 2 units which are heterocycles selected from the group consisting of:
  • R 2 units which are selected from the group consisting of:
  • a further aspect of the present invention relates to W 2 units having the formula: —(CH 2 ) y —R 2 the index y is 1, 2, or 3 and R 2 is selected from the group consisting of:
  • Non-limiting examples of W 2 units comprising this aspect have the formula:
  • a further aspect of R 2 includes substituted or unsubstituted 6-member ring heterocycles selected from the group consisting of pyranyl, 1,4-dioxanyl, morpholinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, 1,4-dithianyl, and thiomorpholinyl.
  • the following precursors can be used to prepare the melanocortin receptor ligands of the present invention.
  • a first precursor useful in preparing melanocortin receptor ligands relates to the hydroxy adduct: 4-cyclohexyl-4-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester via the scheme outlined below.
  • reaction solution is filtered to remove the catalyst and the filtrated is concentrated in vacuo to afford a residue which is partitioned between saturated NaHCO 3 and methylene chloride.
  • organic phase is removed and the aqueous phase washed several times with methylene chloride.
  • the organic layers are combined, dried and concentrated under in vacuo to afford the desired product in nearly quantitative yield as a waxy solid.
  • melanocortin receptor ligands From intermediate compound 3, a series of other precursors useful in preparing melanocortin receptor ligands can be obtained.
  • the mesylate 4 can be used to introduce a variety of 4-position-substituted piperidine, for example, triazole 5:
  • reaction is quenched with a saturated solution of NaHCO 3 and the resulting mixture is extracted twice with dichloromethane (50 mL). The organic layers are combined, dried, filtered and concentrated in vacuo to yield the desired product in quantitative yield. The material is used for the next step without need for purification.
  • the intermediate aldehyde 7 can be used to prepare various W 2 units.
  • Reagents and Conditions (a) (CH 3 O) 3 P(O)CH 2 CO 2 CH 3 , DBU, CH 3 CN; rt, 1 hr. (b) H 2 :Pd/C, MeOH; rt, 2 hr. (c) DIBAL, CH 2 Cl 2 ; rt, 40 min. (d) TosMIC, NaCN, EtOH; rt, 3 hr.
  • reaction is stirred at room temperature for 40 min before it is quenched by adding methanol (3 mL) and water (20 mL).
  • methanol 3 mL
  • water 20 mL
  • the reaction mixture is warmed to room temperature and the organic layer separated, dried over sodium sulfate, filtered and concentrated in vacuo to afford 915 mg (>99% yield) of the desired compound as a colorless oil.
  • Reagents and Conditions (a) (i) 2-aminothiazole, toluene; Reflux 18 hr;(ii) HB(AcO) 3 , rt 3 hr.
  • reaction mixture is stirred for 1.0 hour and then diluted with ethyl acetate and filtered through a pad of Celite.
  • the filtrate is concentrated under reduced pressure and the residue purified over silica (methylene chloride/acetone, 3:1) to afford 629 mg (78% yield) of the desired compound as a colorless solid.
  • the first aspect of Category I melanocortin receptor ligands comprises the 4-cyclohexylpiperidines having the general scaffold with the formula:
  • W 1 comprises a carbocyclic ring
  • R, R 2 , and Q are defined herein below in Table I. TABLE I No. R R 2 W 1 Q 1
  • 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl iso-propyl 5
  • reaction is allowed to stir for 6 hours after which it is quenched by adding aqueous NH 4 Cl.
  • the reaction mixture is extracted with EtOAc and the combined layers are dried, concentrated in vacuo, and the resulting crude product purified over silica gel to afford the desired product.
  • W 1 units which can suitably replace cyclohexyl include, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclopentanone-2-yl, and cycloheptanyl.
  • Non-limiting examples of other analogs of Category I which can be prepared by this process include:
  • the second aspect of Category I melanocortin receptor ligands comprises the 4-cyclohexylpiperidines having the general scaffold with the formula:
  • W 1 comprises a heterocyclic ring
  • R, R 2 , and Q are defined herein below in Table II. TABLE II No. R R 2 W 1 Q 61 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl methyl 62 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl ethyl 63 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl propyl 64 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl iso-propyl 65 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl butyl 66 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl iso-butyl 67 4-chlorophenyl [1,2,4]triazol-1-yl piperid
  • the ice bath is removed and the solution allowed to warm to room temperature and continue stirring overnight. The next morning water is added and the reaction mixture extracted with dichloromethane. The organic layer is collected, dried over sodium sulfate, filtered and the solvent was removed under reduced pressure.
  • the resulting crude product is a mixture of the desired product and 3-[2-(R)-tert-butoxy-carbonylamino-3-(4-chloro-phenyl)-propionyl]-3-aza-7-azonia-dispiro[5.0.5.1 ]tridecane chloride, 24.
  • the crude products are separated by preparative HPLC to afford 121.6 mg (30% yield) of the desired product and 231.9 mg (56% yield) of the major by product, 24.
  • Other units which are suitable for W 1 under aspect 2 of Category II analogs include: phenyl, pyridin-4-yl, piperidin-4-yl, morpholin-4-yl, pyrazin-1-yl, pyran-4-yl, and the like.
  • the third aspect of Category I melanocortin receptor ligands comprises the 4-cyclohexylpiperidines having the general scaffold with the formula:
  • W 1 comprises a heterocyclic ring
  • R, R 2 , and Q are defined herein below in Table III. TABLE III No. R R 2 W 1 Q 121 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl methyl 122 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl ethyl 123 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl propyl 124 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl iso-propyl 125 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl butyl 126 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl iso-butyl 127 4-chlorophenyl [1,2,4]triazol-1-yl
  • reaction is allowed to stir for 6 hours after which it is quenched by adding aqueous NH 4 Cl.
  • the reaction mixture is extracted with EtOAc and the combined layers are dried, concentrated in vacuo, and the resulting crude product purified over silica gel to afford the desired product.
  • the mixture is purged with a hydrogen flow and then stirred for two hours under a hydrogen atmosphere at atmospheric pressure.
  • the reaction mixture is then filtered through a short pad of Celite, and the filtrate concentrated under reduced pressure.
  • the crude product is purified by preparative HPLC to afford desired compound as the trifluoroacetic acid salt.
  • the following precursors can be used to prepare the melanocortin receptor ligands which comprise Category II of the present invention. These precursors can be combined with the precursors which are utilized in preparing the 4,4-disubstituted piperidine scaffolds which comprise Category I described herein above.
  • a first precursor useful in preparing melanocortin receptor ligands relates to the 3-(4-chlorophenyl)propionic acid derivatives available via the scheme outlined below.
  • the first aspect of Category II melanocortin receptor ligands according to the present invention comprises the 4-cyclohexylpiperidines having the general scaffold with the formula:
  • R, R 2 , R 4a , R 4b , Q, and the index j are defined herein below in Table IV. TABLE IV No. R R 2 R 4a R 4b j Q 181 4-fluorophenyl [1,2,4]triazol-1-yl H H 1 phenyl 182 4-fluorophenyl [1,2,4]triazol-1-yl H —CH 3 1 phenyl 183 4-fluorophenyl [1,2,4]triazol-1-yl H —NH 2 1 phenyl 184 4-fluorophenyl [1,2,4]triazol-1-yl H —NHCH 3 1 phenyl 185 4-fluorophenyl [1,2,4]triazol-1-yl H —NHC(O)CH 3 1 phenyl 186 4-fluorophenyl [1,2,4]triazol-1-yl —CH 3 H 1 phenyl 187 4-fluorophenyl [1,2,4]tria
  • the reaction is diluted with water (4400 mL) and extracted with ethyl acetate (3 ⁇ 2400 mL). The combined organic extracts are washed successively with water (2 ⁇ 2000 mL) and saturated aqueous sodium chloride (2000 mL). The organics layers are separated, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified over silica (2:3 ethyl acetate:hexanes) to afford 75.1 g (77.7% yield) of the desired compound as a solid.
  • Hydrogen peroxide (87 mL, 50 wt. % solution in water, 1500 mmol) is then added over forty minutes and the resulting solution heated at 95° C. for an additional eighteen hours. Additional hydrogen peroxide (40 mL 690 mmol) is added and the mixture heated to reflux for five hours followed by cooling to 40° C. The reaction mixture is poured over ice (8000 mL) and then acidified to pH 2.1 with ice-cold 2 M sulfuric acid. The resulting suspension is vigorously stirred for fifteen minutes and the resulting solid collected by filtration. The solid is washed with water (2 ⁇ 500 mL) and dried to constant weight in vacuo. The crude product is used without further purification.
  • the aqueous layer is removed and extracted with ethyl acetate (2 ⁇ 500 mL).
  • the combined organic layers are washed with saturated aqueous sodium chloride (2 ⁇ 750 mL), dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to a residue which is then triterated with ether (400 mL).
  • the mixture is diluted with hexanes (400 mL) and concentrated under reduced pressure to a thick slurry.
  • the resulting solid is collected by filtration, rinsed with hexanes (2 ⁇ 100 mL) and dried to a constant weight in vacuo to give 49.2 g (90% yield) of the desired compound which is used without further purification.
  • the resulting solution is stirred at ⁇ 1° C. for ninety minutes and then warmed to room temperature overnight.
  • the reaction is diluted with methylene chloride (1000 mL), cooled to 0° C., and washed successively with ice-cold 1M potassium hydrogen sulfate (3 ⁇ 700 mL), water (1000 mL) and saturated aqueous sodium chloride (1000 mL).
  • the organics were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to a yellow residue.
  • the residue is dissolved in a 1:1 mixture of methylene chloride/ether (300 mL), diluted with hexanes (150 mL), and then concentrated under reduced pressure to a thick slurry.
  • the resulting solid is collected by filtration, rinsed with ethyl ether (100 mL) and dried to constant weight in vacuo to afford 120.0 g (94% yield) of the desired compound which is used without further purification.
  • the crude product was purified by chromatography on silica gel (methylene chloride:ethyl acetate 4:1-3:1) and the pure fractions were collected and concentrated under reduced pressure.
  • the residue was dissolved in ethyl ether (200 mL) and the resulting solution was diluted with hexanes (100 mL) and then concentrated at 0° C. in vacuo to a thick slurry.
  • the solid was collected by filtration and rinsed with 5% ethyl ether in hexanes (100 mL) and then dried to constant weight in vacuo to give 26.5 g (87% yield) of the desired compound.
  • the resulting solution is warmed to 0° C. for thirty minutes and then cooled to ⁇ 70° C. and 4-fluorobenzyl bromide (5.2 g, 27.5 mmol) is added.
  • the resulting solution is stirred at ⁇ 70° C. for forty minutes and then quenched with saturated aqueous ammonium chloride (200 mL).
  • the organic solvents are removed under reduced pressure and the remaining aqueous layer is extracted with ethyl acetate (1000 mL).
  • the organic layer is separated and washed with water (200 mL) and saturated aqueous sodium chloride (200 mL).
  • the organics are dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure.
  • the resulting reaction mixture is stirred at 0° C. for five minutes and then 30% aqueous hydrogen peroxide solution (12 mL) is added over five minutes.
  • the resulting solution was stirred at room temperature for one hour and then allowed to stir for eighteen hours.
  • the organics solvent was removed under reduced pressure and the remaining residue partitioned between methylene chloride (1000 mL) and water (400 mL). Potassium hydrogen sulfate (200 mL, 1 M solution), was then added and the organics separated and washed with 10% aqueous sodium hydrogen sulfate (2 ⁇ 500 mL), water (500 mL) and saturated aqueous sodium chloride (500 mL).
  • the second aspect of Category II relates to compounds having the formula: wherein either R 3a and R 3b or R 4a and R 4b are taken together to form a carbonyl unit.
  • R 3a and R 3b or R 4a and R 4b are taken together to form a carbonyl unit.
  • the following are non-limiting examples which particularly point out examples of compounds comprising the second aspect of Category II analogs.
  • R, R 2 and Q are defined herein below in Table V. TABLE V No. R R 2 W 1 Q 261 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CO 2 H 262 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONH 2 263 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONHCH 3 264 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONH(CH 3 ) 2 265 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONHSO 2 CH 3 266 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl —CO 2 H 267 4-chlorophenyl 2H-tetrazol-5-yl cycl
  • reaction mixture is stirred overnight and then aqueous ammonium chloride is added.
  • reaction is extracted with ethyl acetate, and the organics are separated dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • the crude product is purified by preparative HPLC to afford the desired compound.
  • R 2 units include —NHC( ⁇ NH)NH 2 , —NHC(O)NH 2 , —NHC( ⁇ NCH 3 )NH 2 , or —NHC( ⁇ NCN)NHNO 2 .
  • Other suitable Q units include quinolinyl, isoquinolinyl, indolyl, tetrahydroquinolinyl, tetrahydrodisoquinolinyl, imidazolyl, and triazolyl.
  • the index j can be 0, 1, or 2.
  • compositions or formulations which comprise the melanocortin receptor ligands according to the present invention also relates to compositions or formulations which comprise the melanocortin receptor ligands according to the present invention.
  • compositions of the present invention comprise:
  • compositions of this invention are typically provided in unit dosage form.
  • unit dosage form is defined herein as comprising an effective amount of one or more melanocortin receptor ligands.
  • the compositions of the present invention contain in one embodiment from about 1 mg to about 750 mg of one or more melanocortin receptor ligands, while in other embodiments the compositions comprise from about 3 mg to about 500 mg, or from about 5 mg to about 300 mg respectively.
  • excipient and “carrier” are used interchangeably throughout the description of the present invention and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
  • excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient.
  • An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach.
  • the formulator can also take advantage of the fact the compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.
  • Non-limiting examples of substances which can serve as pharmaceutically-acceptable excipients or components thereof are sugars, inter alia, lactose, glucose and sucrose, sorbitol, mannitol; starches, inter alia, corn starch and potato starch; cellulose and its derivatives, inter alia, sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; vegetable oils, propylene glycol, glycerin, and polyethylene glycol; agar; alginic acid; wetting agents and lubricants, inter alia, sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and buffers.
  • sugars inter alia, lactose, glucose and sucrose,
  • the present invention further relates to forms of the present compounds, which under normal human or higher mammalian physiological conditions, release the compounds described herein.
  • One iteration of this aspect includes the pharmaceutically acceptable salts of the analogs described herein.
  • the formulator for the purposes of compatibility with delivery mode, excipients, and the like, can select one salt form of the present analogs over another since the compounds themselves are the active species which mitigate the disease processes described herein.
  • pro-drug forms of the analogs of the present invention. It may be desirable to formulate the compounds of the present invention as a chemical species which itself is not a melanocortin receptor ligand as described herein, but instead are forms of the present analogs which when delivered to the body of a human or higher mammal will undergo a chemical reaction catalyzed by the normal function of the body, inter alia, enzymes present in the stomach, blood serum, said chemical reaction releasing the parent analog. Or alternatively, said “pro-drug” form may cross the blood/brain barrier before undergoing a change which releases the melanocortin receptor ligand in its active form.
  • pro-drug relates to these species which are converted in vivo to the active pharmaceutical.
  • the present invention also relates to a method for controlling one or more melanocortin receptor, MC-3 or MC-4, mediated or melanocortin receptor modulated mammalian diseases or conditions, said method comprising the step of administering to a human or higher mammal an effective amount of a composition comprising one or more of the melanocortin receptor ligands according to the present invention.
  • melanocortin receptor ligands of the present invention can be delivered in a manner wherein more than one site of control can be achieved, more than one disease state can be modulated at the same time.
  • diseases which are affected by an antagonist or agonist which stimulates the MC-3 or MC-4 receptor obesity and other body weight disorders, inter alia, anorexia and cachexia.
  • melanocortin receptor ligands of the present invention will therefore affect a variety of diseases, disease states, conditions, or syndromes resulting from body weight disorders, inter alia, insulin resistance, glucose intolerance, Type-2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, cancer (e.g., endometrial, cervical, ovarian, breast, prostate, gallbladder, colon), menstrual irregularities, hirsutism, infertility, gallbladder disease, restrictive lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease.
  • body weight disorders inter alia, insulin resistance, glucose intolerance, Type-2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, cancer (e.g., endometrial, cervical, ovarian, breast, prostate, gallbladder, colon), menstrual irregularities, hirsutism, infertility, gallbla
  • MC-3 and MC-4 receptor ligands are also effective in treating disorders relating to behavior, memory (including learning), cardiovascular function, inflammation, sepsis, cardiogenic and hypovolemic shock, sexual dysfunction, penile erection, muscle atrophy, nerve growth and repair, intrauterine fetal growth, and the like.
  • melanocortin receptor ligands of the present invention are discrete chemical entities, the method of delivery or the method of use may be coupled with other suitable drug delivery systems.
  • a drug delivery technique useful for the compounds of the present invention is the conjugation of the compound to an active molecule capable of being transported through a biological barrier (see e.g. Zlokovic, B. V., Pharmaceutical Research , Vol. 12, pp. 1395-1406 (1995)).
  • a specific example constitutes the coupling of the compound of the invention to fragments of insulin to achieve transport across the blood brain barrier (Fukuta, M., et al. Pharmaceutical Res ., Vol. 11, pp. 1681-1688 (1994)).
  • the compounds of the present invention can be evaluated for efficacy, for example, measurements of cytokine inhibition constants, K i , and IC 50 values can be obtained by any method chosen by the formulator.
  • Non-limiting examples of suitable assays include:
  • Functional activity in vitro pre-screening can be evaluated using various methods known in the art. For example, measurement of the second messenger, cAMP, as described in citation (iv) above, evaluation by Cytosensor Microphysiometer techniques (Boyfield et al. 1996), or by using the compounds of the invention alone, or in combination with natural or synthetic MSH-peptides.
  • the compounds of the present invention will interact preferentially (i.e., selectively) to MC-4 and/or MC-3, relative to the other melanocortin receptors. Selectivity is particularly important when the compounds are administered to humans or other animals, to minimize the number of side effects associated with their administration.
  • MC-3/MC-4 selectivity of a compound is defined herein as the ratio of the EC 50 of the compound for an MC-1 receptor (“EC 50 -MC-1”) over the EC 50 of the compound for the MC-3 (EC 50 -MC-3)/MC-4 (EC 50 -MC-4) receptor, the EC 50 values being measured as described above.
  • a receptor ligand is defined herein as being “selective for the MC-3 receptor” when the above-mentioned ratio “MC-3-selectivity” is at least about 10. In other treatments, methods, or compositions this value is at least about 100, while for yet other embodiments of the present invention the selectivity is at least about 500.
  • a compound is defined herein as being “selective for the MC-4 receptor” when the above-mentioned ratio “MC-3-selectivity” is at least about 10. In other treatments, methods, or compositions this value is at least about 100, while for yet other embodiments of the present invention the selectivity is at least about 500.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)

Abstract

The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula:
Figure US20050171158A1-20050804-C00001
 wherein preferably R is substituted aryl, W is a pendant unit having the formula:
-L-Q
L is a linking unit, Q is preferably a cyclic hydrocarbyl unit; W1 is preferably a carbocyclic unit and W2 is a heteroatom comprising unit.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation of application Ser. No. 10/410,775, filed Apr. 9, 2003, which claims priority under Title 35, United States Code 119(e) from Provisional Application Ser. No. 60/376,585, filed Apr. 30, 2002.
    • FIELD OF THE INVENTION
  • The present invention relates to melanocortin (MC) receptor ligands that have a 4-substituted piperidine ring, which provides for enhanced activity. These ligands preferably exhibit selectivity for the MC-3 and/or MC-4 receptors relative to the other melanocortin receptors (in particular the MC-1 receptor) and are suitable for use in pharmaceutical compositions and in treatment methods.
    • BACKGROUND OF THE INVENTION
  • Melanocortin peptides (melanocortins) are natural peptide hormones in animals and man that bind to and stimulate MC receptors. Examples of melanocortins are α-MSH (melanocyte stimulating hormone), β-MSH; γ-MSH, ACTH (adrenocorticotropic hormone) and their peptide fragments. MSH is mainly known for its ability to regulate peripheral pigmentation, whereas ACTH is known to induce steroidoneogenesis. The melanocortin peptides also mediate a number of other physiological effects. They are reported to affect motivation, learning, memory, behavior, inflammation, body temperature, pain perception, blood pressure, heart rate, vascular tone, natriuresis, brain blood flow, nerve growth and repair, placental development, aldosterone synthesis and release, thyroxin release, spermatogenesis, ovarian weight, prolactin and FSH secretion, uterine bleeding in women, sebum and pheromone secretion, sexual activity, penile erection, blood glucose levels, intrauterine fetal growth, food motivated behavior, as well as other events related to parturition.
  • Both the MC-4 and MC-3 receptors have been localized to the hypothalamus, a region of the brain believed to be involved in the modulation of feeding behavior. Compounds showing selectivity for the MC-3/MC-4 receptors have been shown to alter food intake following intracerebroventricular and peripheral injection in rodents. Specifically, agonists have been shown to reduce feeding, while antagonists have been shown to increase feeding. The role of the MC-4 and MC-3 receptors have been defined in the control of body weight regulation in mammals. It is believed that the MC-3 receptor influences feed efficiency and the partitioning of fuel stores into fat, whereas the MC-4 receptor regulates food intake and possibly energy expenditure. Thus, these receptor subtypes appear to reduce body weight through distinct and complementary pathways. Therefore compounds that stimulate both the MC-3 and MC-4 receptors may have a greater weight loss effect than those that are selective for either the MC-3 or MC-4 receptor.
  • Body weight disorders such as obesity, anorexia and cachexia are widely recognized as significant public health issues and there is a need for compounds and pharmaceutical compositions which can treat these disorders.
  • The Applicants have discovered a class of compounds that surprisingly have high affinity for the MC-4 and/or the MC-3 receptor subtypes, and that are typically selective for these MC receptors relative to the other melanocortin receptor subtypes, particularly the MC-1 subtype.
    • SUMMARY OF THE INVENTION
  • The present invention relates to the surprising discovery that certain 4,4-disubstituted piperidines are affective as melanocortin receptor ligands. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula:
    Figure US20050171158A1-20050804-C00002
    wherein R is a substituted or unsubstituted hydrocarbyl unit selected from the group consisting of:
      • a) non-aromatic carbocyclic rings;
      • b) aromatic carbocyclic rings;
      • c) non-aromatic heterocyclic rings; and
      • d) aromatic heterocyclic rings;
      • W is a pendant unit having the formula:
        -L-Q
        wherein Q is hydrogen or a substituted or unsubstituted unit selected from:
      • i) C1-C22 linear or branched alkyl;
      • ii) C2-C22 linear or branched alkenyl;
      • iii) C2-C22 linear or branched alkynyl;
      • iv) C3-C13 aromatic heterocyclic rings;
      • v) C3-C8 non-aromatic carbocyclic rings;
      • vi) C6-C14 aromatic carbocyclic rings;
      • vii) C1-C7 non-aromatic heterocyclic rings;
      • viii) C3-C13 aromatic heterocyclic rings;
      • xix) —(CH2)mCO2R8;
      • xx) —(CH2)mC(O)N(R8)2; and
      • xxi) —SO2R9;
      • each R8 is hydrogen; substituted or unsubstituted C1-C6 linear, branched, or cyclic alkyl; —OH; —SO2R9, and mixtures thereof; R9 is C1-C4 alkyl or phenyl; the index m is 0, 1, or 2;
      • L is a linking group having the formula:
        Figure US20050171158A1-20050804-C00003
      • T is selected from the group consisting of:
      • i) —NR6S(O)2—;
      • ii) —S(O)2NR6—; and
      • iii) mixtures thereof;
      • the index w is 0 or 1;
      • R3a, R3b, R4a, and R4b are each independently:
      • i) hydrogen;
      • ii) C1-C4 linear, branched, and cyclic alkyl;
      • iii) —N(R6)2;
      • iv) —NR6C(Y)R6;
      • v) R3a and R3b or R4a, and R4b can be taken together to form a carbonyl unit; and
      • vi) mixtures thereof;
      • Y is —O—, —S—, ═O, ═S, ═NR6, ═NOH, and mixtures thereof; the index j is from 0 to 3; the index k is from 0 to 3;
      • W1 is a pendant unit having the formula:
        —(CH2)x—R1
      • R1 is:
      • i) hydrogen;
      • ii) C3-C8 substituted or unsubstituted non-aromatic carbocyclic rings;
      • iii) C6-C14 substituted or unsubstituted aromatic carbocyclic rings;
      • iv) C1-C7 substituted or unsubstituted non-aromatic heterocyclic rings; or
      • v) C3-C13 substituted or unsubstituted aromatic heterocyclic rings;
      • the index x is from 0 to 10;
      • W2 is a pendant unit having the formula:
        Figure US20050171158A1-20050804-C00004
      • R2 is:
      • i) hydrogen;
      • ii) C3-C8 non-aromatic carbocyclic rings;
      • iii) C6-C14 aromatic carbocyclic rings;
      • iv) C1-C7 non-aromatic heterocyclic rings;
      • v) C3-C13 aromatic heterocyclic rings;
      • vi) —C(Y)R6;
      • vii) —C(Y)2R6;
      • viii) —C(Y)N(R6)2;
      • ix) —C(Y)NR6N(R6)2;
      • x) —CN;
      • xi) —CNO;
      • xii) —[C(R7)2]C(R7)2;
      • xiii) —N(R6)2;
      • xiv) —NR6CN;
      • xv) —NR6C(Y)R6;
      • xvi) —NR6C(Y)N(R6)2;
      • xvii) —NHN(R6)2;
      • xviii) —NHOR6;
      • xix) —NCS;
      • xx) —NO2;
      • xxi) —OR6;
      • xxii) —OCN;
      • xxiii) —OCF3, —OCCl3, —OCBr3;
      • xxiv) —F, —Cl, —Br, —I, and mixtures thereof;
      • xxv) —SCN;
      • xxvi) —SO3M;
      • xxvii) —OSO3M;
      • xxviii) —SO2N(R6)2;
      • xxix) —SO2R6;
      • xxx) —[C(R6)2]nP(O)(OR6)R6;
      • xxxi) —[C(R6)2]nP(O)(OR6)2;
      • xxxii) and mixtures thereof;
      • R5a and R5b are each hydrogen, or R5a and R5b are taken together to form a carbonyl unit; Y is —O—, —S—, ═O, ═S, ═NR6, ═NOH, and mixtures thereof; R6 is hydrogen, C1-C4 linear, branched or cyclic alkyl, C2-C4 linear alkenyl, halogen, —OH, —NO2, —CN, and mixtures thereof; M is hydrogen or a salt forming cation;
      • the index y is from 0 to 10.
  • These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (° C.) unless otherwise specified. All documents cited are in relevant part, incorporated herein by reference.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to melanocortin (MC) receptor ligands. The melanocortin (MC) class of peptides mediates a wide range of physiological effects. Synthetic peptides and peptide mimetics, which modulate the interaction of natural MC ligands have varying degrees of selectivity and binding. The present invention is directed to ligands that are selective for the MC4 receptor, or that are selective for both the MC4 and MC3 receptor while minimizing the interaction at the MC1, MC2, and MC5 receptors.
  • For the purposes of the present invention the term “hydrocarbyl” is defined herein as any organic unit or moiety which is comprised of carbon atoms and hydrogen atoms. Included within the term hydrocarbyl are the heterocycles which are described herein below. Examples of various unsubstituted non-heterocyclic hydrocarbyl units include pentyl, 3-ethyloctanyl, 1,3-dimethylphenyl, cyclohexyl, cis-3-hexyl, 7,7-dimethylbicyclo[2.2.1]-heptan-1-yl, and naphth-2-yl.
  • Included within the definition of “hydrocarbyl” are the aromatic (aryl) and non-aromatic carbocyclic rings, non-limiting examples of which include cyclopropyl, cyclobutanyl, cyclopentanyl, cyclohexane, cyclohexenyl, cycloheptanyl, bicyclo-[0.1.1]-butanyl, bicyclo-[0.1.2]-pentanyl, bicyclo-[0.1.3]-hexanyl (thujanyl), bicyclo-[0.2.2]-hexanyl, bicyclo-[0.1.4]-heptanyl(caranyl), bicyclo-[2.2.1]-heptanyl(norboranyl), bicyclo-[0.2.4]-octanyl(caryophyllenyl), spiropentanyl, diclyclopentanespiranyl, decalinyl, phenyl, benzyl, naphthyl, indenyl, 2H-indenyl, azulenyl, phenanthryl, anthryl, fluorenyl, acenaphthylenyl, 1,2,3,4-tetrahydronaphthalenyl, and the like.
  • In addition, within the definition of “hydrocarbyl” is included the term “heterocycle.” The term “heterocycle” includes both aromatic (heteroaryl) and non-aromatic heterocyclic rings non-limiting examples of which include: pyrrolyl, 2H-pyrrolyl, 3H-pyrrolyl, pyrazolyl, 2H-imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, isoxazolyl, oxazoyl, 1,2,4-oxadiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-pyran-2-one-yl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, s-triazinyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 1,4-oxazinyl, morpholinyl, azepinyl, oxepinyl, 4H-1,2-diazepinyl, indenyl 2H-indenyl, benzofuranyl, isobenzofuranyl, indolyl, 3H-indolyl, 1H-indolyl, benzoxazolyl, 2H-1-benzopyranyl, quinolinyl, isoquinolinyl, quinazolinyl, 2H-1,4-benzoxazinyl, pyrrolidinyl, pyrrolinyl, quinoxalinyl, furanyl, thiophenyl, benzimidazolyl, and the like each of which can be substituted or unsubstituted.
  • An example of a unit defined by the term “alkylenearyl” is a benzyl unit having the formula:
    Figure US20050171158A1-20050804-C00005
    whereas an example of a unit defined by the term “alkyleneheteroaryl” is a 2-picolyl unit having the formula:
    Figure US20050171158A1-20050804-C00006
  • The terms “arylene” and “heteroarylene” relate to aryl and heteroaryl units which can serve as part of a linking group, for example, units having the formula:
    Figure US20050171158A1-20050804-C00007
    which represent an arylene and heteroarylene unit respectively.
  • The term “substituted” is used throughout the specification. The term “substituted” is defined herein as “encompassing moieties or units which can replace a hydrogen atom, two hydrogen atoms, or three hydrogen atoms of a hydrocarbyl moiety. Also substituted can include replacement of hydrogen atoms on two adjacent carbons to form a new moiety or unit.” For example, a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like. A two hydrogen atom replacement includes carbonyl, oximino, and the like. A two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like. Three hydrogen replacement includes cyano, and the like. An epoxide unit is an example of a substituted unit which requires replacement of a hydrogen atom on adjacent carbons. The term substituted is used throughout the present specification to indicate that a hydrocarbyl moiety, inter alia, aromatic ring, alkyl chain, can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as “substituted” any number of the hydrogen atoms may be replaced. For example, 4-hydroxyphenyl is a “substituted aromatic carbocyclic ring”, (N,N-dimethyl-5-amino)octanyl is a “substituted C8 alkyl unit, 3-guanidinopropyl is a “substituted C3 alkyl unit,” and 2-carboxypyridinyl is a “substituted heteroaryl unit.”
  • The following are non-limiting examples of units which can serve as a replacement for hydrogen atoms when a hydrocarbyl unit is described as “substituted.” Non-limiting examples include:
      • i) —[C(R6)2]p(CH═CH)qR6; wherein p is from 0 to 12; q is from 0 to 12;
      • ii) —C(Y)R6;
      • iii) —C(Y)2R6;
      • iv) —C(Y)CH═CH2;
      • v) —C(Y)N(R6)2;
      • vi) —C(Y)NR6N(R6)2;
      • vii) —CN;
      • viii) —CNO;
      • ix) —CF3, —CCl3, —CBr3;
      • x) —N(R6 )2;
      • xi) —NR6CN;
      • xii) —NR6C(Y)R6;
      • xiii) —NR6C(Y)N(R6)2;
      • xiv) —NHN(R6)2;
      • xv) —NHOR6;
      • xvi) —NCS;
      • xvii) —NO2;
      • xviii) —OR6;
      • xix) —OCN;
      • xx) —OCF3, —OCCl3, —OCBr3;
      • xxi) —F, —Cl, —Br, —I, and mixtures thereof;
      • xxii) —SCN;
      • xxiii) —SO3M;
      • xxiv) —OSO3M;
      • xxv) —SO2N(R6)2;
      • xxvi) —SO2R6;
      • xxvii) —[C(R7)2]nP(O)(OR6)R6;
      • xxviii) —[C(R7)2]nP(O)(OR6)2;
      • xxix) and mixtures thereof;
        wherein R6 is hydrogen, C1-C4 linear, branched, or cyclic alkyl, halogen, —OH, —NO2, —CN, and mixtures thereof; R7 is hydrogen or halogen, and mixtures thereof; M is hydrogen, or a salt forming cation; Y is —O—, —S— ═O, ═S, ═NR6, ═NOH, and mixtures thereof. Suitable salt forming cations include, sodium, lithium, potassium, calcium, magnesium, ammonium, and the like. Non-limiting examples of an alkylenearyl unit include benzyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl.
  • The compounds of the present invention include all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts of compounds having the core scaffold represented by the formula:
    Figure US20050171158A1-20050804-C00008
    wherein R is a substituted or unsubstituted hydrocarbyl unit selected from the group consisting of:
      • a) non-aromatic carbocyclic rings;
      • b) aromatic carbocyclic rings;
      • c) non-aromatic heterocyclic rings;
      • d) aromatic heterocyclic rings.
  • A first aspect of R units relates to substituted and non-substituted aryl units wherein R units are substituted or unsubstituted phenyl, benzyl, naphthyl, and naphthalen-2-ylmethyl.
  • A first iteration of this aspect encompasses R units which are selected from the group consisting of phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, and 4-methylphenyl. An example of this aspect which is particularly effective in enhancing MC-4 activity is 4-chlorophenyl, especially when combined with W1 units comprising a carbocyclic ring, for example, cyclohexyl.
  • A second iteration of this aspect encompasses R units which are selected from the group consisting of 1-naphthyl, 2-naphthyl, naphthalen-1-ylmethyl, naphthalen-2-ylmethyl, and 1-hydroxynaphthalen-2-ylmethyl.
  • A second aspect of R units relates to substituted and non-substituted heteroaryl units wherein R units comprise substituted or unsubstituted quinolinyl, isoquinolinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl.
  • A first iteration of this aspect encompasses R units which are 1,2,3,4-tetrahydroisoquinolinyl and 1,2,3,4-tetrahydroquinolinyl.
  • A second iteration of this aspect encompasses R units which are 6-hydroxy-1,2,3,4-tetrahydroisoquinolinyl and 6-hydroxy-1,2,3,4-tetrahydroquinolinyl.
  • Another aspect of R relates to phenyl rings comprising a C1-C4 alkyl unit, non-limiting examples of which include 4-methylphenyl, 2,4-dimethylphenyl, as well as mixed alkyl rings, inter alia, 2-methyl-4-isopropyl.
  • A yet further aspect of R relates to substituted or unsubstituted heteroaryl rings selected from the group consisting of thiophenyl, furanyl, oxazolyl, thiazolyl, pyrrolyl, and pyridinyl.
  • W is a pendant unit having the formula:
    -L-Q
    wherein Q is hydrogen or a substituted or unsubstituted unit selected from:
      • i) C1-C22 linear or branched alkyl;
      • ii) C2-C22 linear or branched alkenyl;
      • iii) C2-C22 linear or branched alkynyl;
      • iv) C3-C13 aromatic heterocyclic rings;
      • v) C3-C8 non-aromatic carbocyclic rings;
      • vi) C6-C14 aromatic carbocyclic rings;
      • vii) C1-C7 non-aromatic heterocyclic rings;
      • viii) C3-C13 aromatic heterocyclic rings;
      • xix) —(CH2)mCO2R8;
      • xx) —(CH2)mC(O)N(R8)2; and
      • xxi) —SO2R9;
        each R8 is hydrogen; substituted or unsubstituted C1-C6 linear, branched, or cyclic alkyl; —OH; —SO2R9, and mixtures thereof; R9 is substituted or unsubstitute C1-C4 alkyl or phenyl; the index m is 0, 1, or 2. One R9 iteration relates to units selected from the group consisting of methyl, ethyl, propyl, iso-propyl, and butyl. Another iteration includes haloalkyl, inter alia, trifluoromethyl.
  • Typically the number of rings which comprise Q are from 1 to 3. Aspects described herein include the substituted and unsubstituted mono-cyclic rings, inter alia, piperidine, pyrazine, pyrrolidine, imidazole, and the like, as well as fused-ring units, inter alia, quinoline, isoquinoline, indole, and the like. Examples of the various aspects of Q are described further herein below. All units which comprise Q can be substituted or unsubstituted by the units described herein above.
  • The first aspect of Q units relates to substituted or unsubstituted fused-ring heterocyclic units comprising 5 to 12 carbon atoms.
  • One iteration of this first aspect of Q units relates to substituted or unsubstituted fused ring heterocycles comprising one nitrogen atom, a first embodiment of which relates to quinoline or isoquinoline rings having the formula:
    Figure US20050171158A1-20050804-C00009
    a second embodiment relates to units having the formula:
    Figure US20050171158A1-20050804-C00010
    and a third embodiment relates to the tetrahydroquinoline and tetrahydroisoquinoline rings having the formula:
    Figure US20050171158A1-20050804-C00011
  • The second aspect of the present invention as it relates to Q units comprises nitrogen-atom containing six-member rings which can optionally further comprise a second nitrogen or other heteroatom, for example, the heteroaryl rings having the formulae:
    Figure US20050171158A1-20050804-C00012
    Other units included in this aspect include: morpholinyl, piperidinyl, triazinyl, and the like.
  • The third aspect of the Q units of the present invention relates to 5-member ring nitrogen atom containing heterocycles. A first iteration of the third aspect of Q relates to heterocycles selected from the group consisting of:
      • i) thiazolyl, 2-methylthiazolyl, 4-mentylthiazolyl, 5-methylthiazolyl having the formula:
        Figure US20050171158A1-20050804-C00013
      • ii) 1,3,4-thiadiazolyl, 2-methyl-1,3,4-thiadiazolyl having the formula:
        Figure US20050171158A1-20050804-C00014
      • iii) 1,2,5-thiadiazolyl, 3-methyl-1,2,5-thiadiazolyl having the formula:
        Figure US20050171158A1-20050804-C00015
      • iv) oxazolyl, 2-methyloxazolyl, 4-methyloxazolyl, 5-methyloxazolyl having the formula:
        Figure US20050171158A1-20050804-C00016
      • v) imidazolyl, 2-methylimidazolyl, 5-methylimidazolyl having the formula:
        Figure US20050171158A1-20050804-C00017
      • vi) 5-methyl-1,2,4-oxadiazolyl, 2-methyl-1,3;4-oxadiazolyl, 5-amino-1,2,4-oxadiazolyl, having the formula:
        Figure US20050171158A1-20050804-C00018
      • vii) 1,2-dihydro[1,2,4]triazol-3-one-1-yl, 2-methyl-1,2-dihydro[1,2,4]triazol-3-one-5-yl, having the formula:
        Figure US20050171158A1-20050804-C00019
      • viii) oxazolidin-2-one-3-yl; 4,4-dimethyloxazolidin-2-one-3-yl; imidazolidin-2-one-1-yl; 1-methylimidazolidin-2-one-1-yl, having the formula:
        Figure US20050171158A1-20050804-C00020
      • ix) 2-methyl-1,3,4-oxadiazolyl, 2-amino-1,3,4-oxadiazolyl, 2-(N,N-dimethylamino)-1,3,4-oxadiazolyl, having the formula:
        Figure US20050171158A1-20050804-C00021
  • A second iteration of this aspect relates to R2 units which are selected from the group consisting of:
      • i) triazoles having the formula:
        Figure US20050171158A1-20050804-C00022
      • ii) tetrazole having the formula:
        Figure US20050171158A1-20050804-C00023
  • A yet other aspect of Q relates to units having the formula:
      • i) —(CH2)mCO2R8; or
      • i) —(CH2)mC(O)N(R8)2;
        each R8 is hydrogen; substituted or unsubstituted C1-C6 linear, branched, or cyclic alkyl; —OH; —SO2R9, and mixtures thereof; R9 is C1-C4 alkyl or phenyl; the index m is 0, 1, or 2.
  • A first iteration of this aspect relates to Q units which are carboxylic acids.
  • A second iteration of this aspect relates to Q units which are amides, non-limiting examples of which include
      • i) C(O)NHCH3;
      • ii) —C(O)NHCH2CH3;
      • ii) —C(O)NHCH(CH3)2;
      • iv) —C(O)NHCH2CH2CH3;
      • v) —C(O)NHCH2CH2CH2CH3;
      • vi) —C(O)NHCH2CH(CH3)2;
      • vii) —C(O)NH2;
      • viii) —C(O)NHCH2CH═CHCH3;
      • xix) —C(O)NHCH2CH2CH(CH3)2; and
      • xx) —C(O)NHCH2C(CH3)3.
  • A third iteration of this aspect relates to Q units which are substituted C1-C6 linear, branched, or cyclic alkyl; non-limiting examples of which include:
      • i) —C(O)NHCH2COH(CH3)2;
      • ii) —C(O)NHCH2CNH2(CH3)2;
      • ii) —C(O)NHCH2CH(CH3)NH2; and
      • iv) —C(O)NHCH2CH(CH3)OH;
      • L is a linking group having had the formula:
        Figure US20050171158A1-20050804-C00024
        wherein T is selected from the group consisting of:
      • i) —NR6S(O)2—;
      • ii) —S(O)2NR6—; and
      • iii) mixtures thereof.
        The index w is 0 or 1.
  • R3a, R3b, R4a, R4b are each independently:
      • i) hydrogen;
      • ii) C1-C4 linear, branched, and cyclic alkyl;
      • iii) —N(R6)2;
      • iv) —NR6C(Y)R6;
      • v) R3a and R3b or R4a and R4b can be taken together to form a carbonyl unit; and
      • vi) mixtures thereof;
      • Y is —O—, —S—, ═O, ═S, ═NR6, ═NOH, and mixtures thereof. R6 is hydrogen, C1-C4 linear, branched or cyclic alkyl, halogen, —NH2, —OH, —NO2, —CN, and mixtures thereof;
  • The index j is from 0 to 3 and the index k is from 0 to 3.
  • A first aspect of L relates to linking groups wherein the index w is equal to 0 and the indices j and k are each equal to 1. This aspect relates to R3a and R3b and R4a and R4b units independently selected from:
      • i) hydrogen;
      • ii) methyl; and
      • iii) mixtures thereof;
        wherein iterations of this aspect relate to linking groups which are alkylene units, non-limiting examples of which have the formula:
        Figure US20050171158A1-20050804-C00025
  • Another aspect of linking groups relates to units comprising at least one unit having the formula:
      • i) —N(R6)2;
      • ii) —NR6C(Y)R6; or
      • iii) R3a and R3b or R4a, and R4b can be taken together to form a carbonyl unit; non-limiting examples of iterations of which have the formula:
        Figure US20050171158A1-20050804-C00026
  • Another aspect of linking units relates to L units which comprise units wherein the indices j and k are each equal to 0, the index w is 1 and T is a unit having the formula:
    Figure US20050171158A1-20050804-C00027
    said units relating to Category I of compounds according to the present invention.
  • W1 is a pendant unit having the formula:
    —(CH2)x—R1
      • R1 is:
      • i) hydrogen;
      • ii) C3-C8 substituted or unsubstituted non-aromatic carbocyclic rings;
      • iii) C6-C14 substituted or unsubstituted aromatic carbocyclic rings;
      • iv) C1-C7 substituted or unsubstituted non-aromatic heterocyclic rings; or
      • v) C3-C13 substituted or unsubstituted aromatic heterocyclic rings;
      • the index x is from 0 to 10.
  • The first aspect of W1 relates units having the formula:
  • having the formula:
    —R1
    wherein the index x is 0. The first embodiment of this aspect relates to R1 units which are substituted or unsubstituted carbocyclic rings selected from the group consisting of cyclopropyl, cyclopentyl, cyclohexyl, 2-methylenecyclopentyl, and cycloheptyl.
  • A second embodiment of this aspect relates to R1 units which are aromatic or non-aromatic heterocyclic rings selected from the group consisting of thiophen-2-yl, piperidin-4-yl, pyridin-2-yl, and morpholin-4-yl.
  • The second aspect of W1 relates to units having the formula:
    —CH2—R1
    wherein the index x is 1. The first embodiment of this aspect relates to R1 units which are substituted and unsubstituted carbocyclic rings selected from the group consisting of cyclopropyl, cyclopentyl, cyclohexyl, 2-methylenecyclopentyl, and cycloheptyl.
  • A second embodiment of this aspect relates to R1 units which are aromatic or non-aromatic heterocyclic rings selected from the group consisting of thiophen-2-yl, piperidin-4-yl, pyridin-2-yl, and morpholin-4-yl.
  • W2 is a pendant unit having the formula:
    Figure US20050171158A1-20050804-C00028
      • R2 is:
      • i) hydrogen;
      • ii) C3-C8 non-aromatic carbocyclic rings;
      • iii) C6-C14 aromatic carbocyclic rings;
      • iv) C1-C7 non-aromatic heterocyclic rings;
      • v) C3-C13 aromatic heterocyclic rings;
      • vi) —C(Y)R6;
      • vii) —C(Y)2R6;
      • viii) —C(Y)N(R6)2;
      • ix) —C(Y)NR6N(R6)2;
      • x) —CN;
      • xi) —CNO;
      • xii) —[C(R7)2]C(R7)2;
      • xiii) —N(R6)2;
      • xiv) —NR6CN;
      • xv) —NR6C(Y)R6;
      • xvi) —NR6C(Y)N(R6)2;
      • xvii) —NHN(R6)2;
      • xviii) —NHOR6;
      • xix) —NCS;
      • xx) —NO2;
      • xxi) —OR6;
      • xxii) —OCN;
      • xxiii) —OCF3, —OCCl3, —OCBr3;
      • xxiv) —F, —Cl, —Br, —I, and mixtures thereof;
      • xxv) —SCN;
      • xxvi) —SO3M;
      • xxvii) —OSO3M;
      • xxviii) —SO2N(R6)2;
      • xxix) —SO2R6;
      • xxx) —[C(R6)2]nP(O)(OR6)R6;
      • xxxi) —[C(R6)2]nP(O)(OR6)2;
      • xxxii) and mixtures thereof;
        each pair of R5a and R5b are either both hydrogen, thereby forming a methylene unit (CH2)—, or R5a and R5b are taken together to form a carbonyl unit; Y is the same as above; R6 is hydrogen, C1-C4 linear, branched or cyclic alkyl, C2-C4 linear alkenyl, halogen, —OH, —NO2, —CN, and mixtures thereof; M is hydrogen or a salt forming cation.
  • The index y is from 0 to 10.
  • One aspect of the present invention relates to W2 units which are short chain alkyl or alkenyl(lower hydrocarbyl) esters, R2 having the formula:
    —C(O)OR6;
    in one iteration R6 is C1-C4 linear branched or cyclic alkyl or alkenyl. Non-limiting examples include —C(O)OCH3; —C(O)OCH2CH3; —C(O)OCH2CH2CH3; —C(O)OCH(CH3)2; —C(O)OCH2CH2CH2CH3; —C(O)OCH2CH(CH3)2; —C(O)OCH2CH═CHCH3; —C(O)OCH2CH2CH(CH3)2; —C(O)OCH2C(CH3)3; and the like.
  • Another aspect of the present invention relates to R2 units which are short chain substituted or non-substituted amides having the formula:
    —C(O)NHR6 or —NHC(O)R6
    in one iteration R6 is C1-C4 linear branched or cyclic alkyl or alkenyl. Non-limiting examples include —C(O)NHCH3; —C(O)NHCH2CH3; —C(O)NHCH(CH3)2; —C(O)NHCH2CH2CH3; —C(O)NHCH2CH2CH2CH3; —C(O)NHCH2CH(CH3)2; —C(O)NH2; —C(O)NHCH2CH═CHCH3; —C(O)NHCH2CH2CH(CH3)2; —C(O)NHCH2C(CH3)3; —C(O)NHCH2CH2SCH3; —C(O)NHCH2CH2OH; —NHC(O)CH3; —NHC(O)CH2CH3; —NHC(O)—CH2CH2CH3; and the like.
  • Another aspect of the present invention as it relates to W2 units encompasses units having the formula:
    —(CH2)y—R2
    wherein the index y is from 1 to 3.
  • A first iteration of this aspect relates to R2 units which are heterocycles selected from the group consisting of:
      • i) thiazolyl, 2-methylthiazolyl, 4-mentylthiazolyl, 5-methylthiazolyl having the formula:
        Figure US20050171158A1-20050804-C00029
      • ii) 1,3,4-thiadiazolyl, 2-methyl-1,3,4-thiadiazolyl having the formula:
        Figure US20050171158A1-20050804-C00030
      • iii) 1,2,5-thiadiazolyl, 3-methyl-1,2,5-thiadiazolyl having the formula:
        Figure US20050171158A1-20050804-C00031
      • iv) oxazolyl, 2-methyloxazolyl, 4-methyloxazolyl, 5-methyloxazolyl having the formula:
        Figure US20050171158A1-20050804-C00032
      • v) imidazolyl, 2-methylimidazolyl, 5-methylimidazolyl having the formula:
        Figure US20050171158A1-20050804-C00033
      • vi) 5-methyl-1,2,4-oxadiazolyl, 2-methyl-1,3,4-oxadiazolyl, 5-amino-1,2,4-oxadiazolyl, having the formula:
        Figure US20050171158A1-20050804-C00034
      • vii) 1,2-dihydro[1,2,4]triazol-3-one-1-yl, 2-methyl-1,2-dihydro[1,2,4]triazol-3-one-5-yl, having the formula:
        Figure US20050171158A1-20050804-C00035
      • viii) oxazolidin-2-one-3-yl; 4,4-dimethyloxazolidin-2-one-3-yl; imidazolidin-2-one-1-yl; 1-methylimidazolidin-2-one-1-yl, having the formula:
        Figure US20050171158A1-20050804-C00036
      • ix) 2-methyl-1,3,4-oxadiazolyl, 2-amino-1,3,4-oxadiazolyl, 2-(N,N-dimethylamino)-1,3,4-oxadiazolyl, having the formula:
        Figure US20050171158A1-20050804-C00037
  • A second iteration of this aspect relates to R2 units which are selected from the group consisting of:
      • i) triazoles having the formula:
        Figure US20050171158A1-20050804-C00038
      • ii) tetrazole having the formula:
        Figure US20050171158A1-20050804-C00039
        Non-limiting examples of scaffolds comprising the heterocycles of this aspect include:
        Figure US20050171158A1-20050804-C00040
  • A further aspect of the present invention relates to W2 units having the formula:
    —(CH2)y—R2
    the index y is 1, 2, or 3 and R2 is selected from the group consisting of:
      • a) —C(O)N(R7)2;
      • b) —C(O)NR7N(R7)2;
      • c) —NR7C(O)N(R7)2; and
      • d) —NR7C(═NR7)N(R7)2;
        R4 is hydrogen, methyl, and mixtures thereof; R7 is hydrogen, methyl, —NO2, —CN, and mixtures thereof.
  • Non-limiting examples of W2 units comprising this aspect have the formula:
      • a) —(CH2)yNHC(O)NH2;
      • b) —(CH2)yNHC(═NH)NH2;
      • c) —(CH2)yNHC(═NCH3)NHCN;
      • d) —(CH2)yNHC(═NNO2)NHCN;
      • e) —(CH2)yNHC(═NCH3)NHNO2;
      • f) —(CH2)yNHC(═NCN)NHNO2; and
      • g) —(CH2)yNHC(═NCN)NH2;
        wherein y is 1, 2, or 3. A first iteration includes W2 units wherein y is equal to 3 and R2 has the formula:
        Figure US20050171158A1-20050804-C00041
  • A further aspect of R2 includes substituted or unsubstituted 6-member ring heterocycles selected from the group consisting of pyranyl, 1,4-dioxanyl, morpholinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, 1,4-dithianyl, and thiomorpholinyl.
    • Preparation of Melanocortin Receptor Ligands
  • The following precursors can be used to prepare the melanocortin receptor ligands of the present invention.
  • A first precursor useful in preparing melanocortin receptor ligands relates to the hydroxy adduct: 4-cyclohexyl-4-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester via the scheme outlined below.
    Figure US20050171158A1-20050804-C00042
  • Preparation of 4-cyclohexylpiperidine-4-carboxylic acid ethyl ester (1): To a solution of 4-phenylpiperidine-4-carboxylic acid ethyl ester (56 g, 248 mmol) in EtOH (700 mL) is added platinum (IV) oxide (10.2 g, 45 mmol) and concentrated hydrochloric acid. The Flask is purged with nitrogen and shaken on a Parr hydrogenation apparatus at 40 psig for 18 hours. The flask is removed and additional PtO2 (2 g, 8.8 mmol) is added and hydrogenation is continued at 40 psig an additional 6 hours. The reaction solution is filtered to remove the catalyst and the filtrated is concentrated in vacuo to afford a residue which is partitioned between saturated NaHCO3 and methylene chloride. The organic phase is removed and the aqueous phase washed several times with methylene chloride. The organic layers are combined, dried and concentrated under in vacuo to afford the desired product in nearly quantitative yield as a waxy solid. 1H NMR (300 MHz, CDCl3) δ 0.90-1.45 (m, 6H), 1.25-1.32 (t, 3H), 1.55-1.85 (m, 7H), 2.15-2.28 (m, 2H), 2.98-2.80 (m, 2H), 3.18-3.27 (m, 2H), 4.10-4.25 (m, 2H), 7.10 (broad s, 1H); MS (ESI) m/z 240, (M+H+).
  • Preparation of (4-cyclohexylpiperidin-4-yl)-methanol (2): To a cooled (−5° C.) solution of lithium aluminum hydride (900 mL, 0.90 moles, 1.0M solution in THF) is added tetrahydrofuran (2000 mL) and 4-cyclohexyl-piperidine-4-carboxylic acid ethyl ester, 1, (59.5 g, 249 mmol). The resulting solution is stirred at between −5° C. and +3° C. for 1 hour and then allowed to warmed to room temperature and stir an additional sixty-six hours. The reaction is then re-cooled to 0° C. and carefully quenched with saturated ammonium chloride (100 mL). The reaction mixture is stirred for 10 minutes and then 87:10:3 ethyl acetate:methanol:triethylamine (500 mL) is added. The suspension is then stirred at room temperature for 20 minutes and filtered through a pad of Celite. The solids are re-suspended in 1:1 THF:EtOAc (2000 mL), stirred at room temperature for 1 hour and the suspension was again filtered through a pad of Celite. The filtrates are combined and concentrated in vacuo to afford 53.6 g of a mixture of the desired compound and 4-cyclohexyl-piperidine-4-carbaldehyde. The crude mixture is used directly in without further purification.
  • Preparation of 4-cyclohexyl-4-hydroxymethylpiperidine-1-carboxylic acid tert-butyl ester (3): Di-tert-butyl dicarbonate (79 g, 362 mmol) is added to a stirred solution of (4-cyclohexyl-piperidin-4-yl)-methanol, 2, (53.6 g) and triethylamine (180 mL) in MeOH (1600 mL) at 0° C. The resulting solution is allowed to warm to room temperature and is stirred an additional 4 hours. The solution concentrated in vacuo and purified via chromatography eluting with EtOAc/hexane 3:2, to afford 35.8 g (48% yield) of the desired product as a white solid. 1H NMR (300 MHz, CDCl3) δ 1.00-1.32 (m, 5H), 1.35-1.60 (m, 14H), 1.65-1.88 (m, 5H), 3.15-3.30 (m, 2H), 3.48-3.65 (m, 2H), 3.63 (s, 2H); MS (ESI) m/z 298, (M+H+).
  • From intermediate compound 3, a series of other precursors useful in preparing melanocortin receptor ligands can be obtained. The mesylate 4 can be used to introduce a variety of 4-position-substituted piperidine, for example, triazole 5:
    Figure US20050171158A1-20050804-C00043
    • Reagents and Conditions: (a) MsCl, Et3N; (b) sodium triazole, DMF
  • or azide 6 which can be used to introduce a variety of functional groups as further described herein below.
    Figure US20050171158A1-20050804-C00044
    • Reagents and Conditions: (a) NaN3, DMF
  • Preparation of 4-cyclohexyl-4-methanesulfonyloxymethylpiperidine-1-carboxylic acid tert-butyl ester (4): Methane sulfonyl chloride (1.8 mL, 23.0 mmol) is added to a stirred solution of 4-cyclohexyl-4-hydroxymethylpiperidine-1-carboxylic acid tert-butyl ester, 3, (3.42 g, 11.48 mmol) and triethylamine (4.8 mL, 2.8 mmol) in dichloromethane (30 mL) at 0° C. The reaction mixture is then allowed to warm to room temperature and stir for 1 hour. The reaction is quenched with a saturated solution of NaHCO3 and the resulting mixture is extracted twice with dichloromethane (50 mL). The organic layers are combined, dried, filtered and concentrated in vacuo to yield the desired product in quantitative yield. The material is used for the next step without need for purification.
  • Preparation of 4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester (5): To a solution of 4-cyclohexyl-4-methansulfonyloxymethyl-piperidine-1-carboxylic acid tert-butyl ester (39 g, 103.8 mmol) in N,N-dimethylformamide (200 mL) is added sodium triazole (38 g, 415.2 mmol). The resulting solution is heated to 100° C. for 24 hours then cooled to room temperature. The solvent is removed under reduce pressure and the crude product purified over silica (80:20 EtOAc:hexane) to afford 28.7g (79.7% yield) of the desired compound as a colorless solid. 1H NMR (CD3OD) δ 0.95-1.90 (m, 15H), 1.46 (s, 9H), 3.45-3.55 (m, 4H), 4.34 (s, 2H), 7.99 (s, 1H), 8.48 (s, 1H). MS (ESI) m/z 349, (M+H+), 371 (M+Na+)
  • Preparation of 4-cyclohexyl-4-azidomethylpiperidine-1-carboxylic acid tert-butyl ester (6): To a solution of 4-cyclohexyl-4-methanesulfonyloxymethyl-piperidine-1-carboxylic acid tert-butyl ester, 4, (2.42 g, 6.73 mmol) in DMF (25 mL) is added sodium azide (1.32 g, 20.2 mmol) and the mixture is heated and stirred at 100° C. over night. The reaction is cooled and then quenched with water. The resulting solution is extracted with EtOAc (30 mL), dried, filtered and concentrated in vacuo to afford the crude product as a brown oil which is purified via chromatography on silica gel eluting with hexane/EtOAc 3:1 to afford the desired product in 76% yield (1.91 g) as a colorless oil.
  • The intermediate aldehyde 7 can be used to prepare various W2 units.
    Figure US20050171158A1-20050804-C00045
    • Reagents and Conditions: (a) (CH3CH2CH2)4NRuO4; 4-methylmorpholine N-oxide; 3 Å Sieves; rt, 1 hr.
  • Preparation of 4-cyclohexyl-4-formyl-piperidine-1-carboxylic acid tert-butyl ester (7): To a mixture of 4-cyclohexyl-4-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester, 3, (1.0 g, 3.36 mmol), 4-methylmorpholine N-oxide (0.54 g, 4.64 mmol), and molecular sieves (0.5 g) in methylene chloride (20 mL) under argon atmosphere is added tetrapropylammonium perruthenate (35.5 mg) at room temperature. The mixture is stirred for 30 min to 1 hour after which the solution is filtered through a pad of silica and the solvent removed in vacuo to afford the desired product as a colorless oil, which is used without further purification. MS (ESI) m/z 318, (M+Na+).
  • The following are non-limiting examples of functional groups and functional group precursors which can be prepared from aldehyde 7.
    Figure US20050171158A1-20050804-C00046
    • Reagents and Conditions: (a) (CH3O)3P(O)CH2CO2CH3, DBU, CH3CN; rt, 1 hr. (b) H2:Pd/C, MeOH; rt, 2 hr. (c) DIBAL, CH2Cl2; rt, 40 min. (d) TosMIC, NaCN, EtOH; rt, 3 hr.
  • Preparation of 4-cyclohexyl-4-(2-methoxycarbonyl-vinyl)-piperidine-1-carboxylic acid tert-butyl ester (8): To a solution of trimethyl phosphonoacetate (1.41 ml, 8.72 mmole), lithium chloride (477 mg, 11.3 mmole), and 1,8-diazabicyclo[4.3.0]non-7-ene (DBU) (1.55 ml, 11.3 mmole) in anhydrous acetonitrile (25 ml) is added 4-cyclohexyl-4-formyl-piperidine-1-carboxylic acid tert-butyl ester, 7, (2.58 mg, 8.72 mmole) under argon at room temperature. The mixture is stirred for one hour and the solvent then removed under reduced pressure. The crude product is purified over silica (methylene chloride:methanol=15:1, Rf=0.78) to afford 2.64 g (86% yield) of the desired compound.
  • Preparation of 4-cyclohexyl-4-(2-methoxycarbonyl-ethyl)-piperidine-1-carboxylic acid tert-butyl ester (9): To a solution of 4-cyclohexyl-4-(2-methoxycarbonyl-vinyl)-piperidine-1-carboxylic acid tert-butyl ester, 8, (2.64 g, 7.5 mmole) in methanol (30 ml) is added 10% palladium on carbon (120 mg) under argon. The mixture is purged with hydrogen and then stirred for two hours under a hydrogen atmosphere at atmospheric pressure. The reaction mixture is filtered through a short pad of Celite and the filtrate concentrated under reduced pressure. The crude product is purified over silica to afford 2.57 g (97% yield) of the desired compound.
  • Preparation of 4-cyclohexyl-4-(3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester (10): To a cooled (−78° C.) solution of 4-cyclohexyl-4-(2-methoxycarbonylethyl)-piperidine-1-carboxylic acid tert-butyl ester, 9, (1.0 g, 2.833 mmol) in 40 ml of anhydrous methylene chloride is added diisobutylaluminum hydride (5.75 ml, 1 M, 5.75 mmol). The reaction is stirred at room temperature for 40 min before it is quenched by adding methanol (3 mL) and water (20 mL). The reaction mixture is warmed to room temperature and the organic layer separated, dried over sodium sulfate, filtered and concentrated in vacuo to afford 915 mg (>99% yield) of the desired compound as a colorless oil.
  • Preparation of 4-cyclohexyl-4-[2-(3H-imidazol-4-yl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester (11): A solution of 4-cyclohexyl-4-(3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester, 10, (300 mg, 0.93) in ethanol (10 ml) is treated with tosylmethyl isocyanide (tosMIC) (176 mg, 0.93 mmole) and sodium cyanide (6 mg) at room temperature for three hours. The solvent is removed under reduced pressure and ammonia in methanol (2M, 10 ml) added. The mixture is stirred in a sealed tube overnight. The reaction mixture is then concentrated under reduced pressure and the residue taken up in chloroform, washed with aqueous sodium bicarbonate, brine, then dried with sodium sulfate and concentrated to a red oil. The residue is purified over silica (methylene chloride:methanol=15:1, Rf=0.58) to afford 141 mg (42% yield) of the desired product.
  • The following scheme utilizes intermediate 3 for the preparation of other analogs intermediates and precursors.
    Figure US20050171158A1-20050804-C00047
    • Reagents and Conditions: (a) (i) 2-aminothiazole, toluene; Reflux 18 hr;(ii) HB(AcO)3, rt 3 hr.
  • Figure US20050171158A1-20050804-C00048
    • Reagents and Conditions: (b) TFA/CH2Cl2/H2O; rt 1 hr.
  • Preparation of 4-cyclohexyl-4-(thiazol-2-ylaminomethyl)-piperidine-1-carboxylic acid tert-butyl ester (12): 4-Cyclohexyl-4-formyl-piperidine-1-carboxylic acid tert-butyl ester, 3, (296 mg, 1.0 mmol) and 2-aminothiazole (103 mg, 1.0 mmol) are dissolved in toluene (15 mL), and the mixture was refluxed using a Dean—Stark apparatus overnight. The solution is then cooled to room temperature and sodium triacetoxyborohydride added. The reaction is stirred at room temperature for three hours and then diluted with ethyl acetate. The reaction mixture is washed with aqueous sodium bicarbonate and brine. The solvent is removed under reduced pressure and the residue purified by preparative HPLC to afford 312 mg (82% yield) of the desired compound. MS (ESI) m/z 380 (M+H+)
  • Preparation of (4-cyclohexyl-piperidin-4-ylmethyl)-thiazol-2-yl-amine (13): A ready-to-use solution of trifluoroacetic acid:methylene chloride:water (1:1:0.1, 7 mL) is added to 4-cyclohexyl-4-(thiazol-2-ylaminomethyl)-piperidine-1-carboxylic acid tert-butyl ester, 12, (312 mg, 0.82 mmol), and the reaction mixture is stirred for 0.5-1.0 hour. The mixture is then concentrated under reduced pressure and partitioned between aqueous sodium bicarbonate and ethyl acetate. The organics are separated and the solvent removed under reduced pressure. The crude product is purified by preparative HPLC to afford 220 mg (96% yield) of the desired compound as the trifluoroacetic acid salt.
  • The following scheme utilizes intermediate 7 for the preparation of other intermediates and precursors.
    Figure US20050171158A1-20050804-C00049
    • Reagents and Conditions: (a) dimethylphosphono acetonitrile, LiCl, DBU; rt 1 hr.
  • Figure US20050171158A1-20050804-C00050
    • Reagents and Conditions: (b) H2, NH3, Raney Ni; rt, 6 hr.
  • Figure US20050171158A1-20050804-C00051
    • Reagents and Conditions: (c) HgCl2, CBzNHC(SCH3)═NCBz, TEA, DMF; rt, 1 hr.
  • Figure US20050171158A1-20050804-C00052
    • Reagents and Conditions: (d) TFA/CH2Cl2/H2O; rt, 1 hr.
  • Preparation of 4-(2-cyanovinyl)-4-cyclohexylpiperidine-1-carboxylic acid tert-butyl ester (14): To a solution of dimethyl phosphono acetonitrile (0.78 mL, 4.02 mmol), LiCl (184 mg, 4.02 mmol), and DBU (0.55 mL, 4.02 mmol) in anhydrous acetonitrile (25 mL) is added 4-cyclohexyl-4-formylpiperidine-1-carboxylic acid tert-butyl ester, 7, (992 mg, 3.35 mmol) under an atmosphere of argon at room temperature. The mixture is stirred for 1 hour and the solvent removed in vacuo. The resulting crude product is purified over silica gel eluting with dichloromethane/methanol 15:1 to afford the desired product in quantitative yield.
  • Preparation of 4-(3-aminopropyl)-4-cyclohexylpiperidine-1-carboxylic acid tert-butyl ester (15): To a solution of 4-(2-cyanovinyl)-4-cyclohexylpiperidine-1-carboxylic acid tert-butyl ester, 14, (800 mg, 2.35 mmol) in MeOH (33 mL) is added ammonia (16 mL) and Raney Ni (50 mg). The reaction mixture is degassed with nitrogen, purged with hydrogen gas and shaken under an atmosphere of hydrogen (45 psi) on a standard hydrogenation apparatus at room temperature for 6 hours. The reaction solution is filtered to remove the catalyst and the solvent removed in vacuo to afford the desired product was obtained as a colorless, sticky oil in quantitative yield.
  • Preparation of 4-cyclohexyl-4-(3-dicabobenzyloxy-guanidino-propyl)-piperidine-1-carboxylic acid tert-butyl ester (16): Mercury(II) chloride (401 mg, 0.48 mmol) is added to a stirred solution of 4-(3-amino-propyl)-4-cyclohexyl-piperidine-1-carboxylic acid tert-butyl ester, 15, (425 mg, 1.23 mmole), 1,3-bis(benzoxycarbonyl)-2-methyl-2-thiopseudo urea (441 mg, 1.23 mmol) and triethylamine (0.62 ml, 5.64 mmol) in N,N-dimethylformamide (15 ml). The reaction mixture is stirred for 1.0 hour and then diluted with ethyl acetate and filtered through a pad of Celite. The filtrate is concentrated under reduced pressure and the residue purified over silica (methylene chloride/acetone, 3:1) to afford 629 mg (78% yield) of the desired compound as a colorless solid.
  • Preparation of N-[3-(4-cyclohexyl-piperidin-4-yl)-propyl]-dicarbobenzyloxy-guanidine (17): A ready-to-use solution of trifluoroacetic acid:methylene chloride:water (1:1:0.1, 11 ml) is added to 4-cyclohexyl-4-(3-dicarbobenzyloxy-guanidino-propyl)-piperidine-1-carboxylic acid tert-butyl ester, 16, (300 mg, 0.46 mmole), and the reaction mixture is stirred for 0.5-1.0 hour. The mixture is then concentrated under reduced pressure and partitioned between aqueous sodium bicarbonate and ethyl acetate. The organics are separated and concentrated under reduced pressure. The crude product is purified by preparative HPLC to afford 254 mg (>99% yield) of the desired compound.
  • The first aspect of Category I melanocortin receptor ligands according to the present invention comprises the 4-cyclohexylpiperidines having the general scaffold with the formula:
    Figure US20050171158A1-20050804-C00053
  • wherein W1 comprises a carbocyclic ring, R, R2, and Q are defined herein below in Table I.
    TABLE I
    No. R R2 W1 Q
    1 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl methyl
    2 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl ethyl
    3 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl propyl
    4 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl iso-propyl
    5 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl butyl
    6 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl iso-butyl
    7 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl tert-butyl
    8 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl trifluoromethyl
    9 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl phenyl
    10 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl naphthalen-2-yl
    11 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl methyl
    12 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl ethyl
    13 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl propyl
    14 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl iso-propyl
    15 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl butyl
    16 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl iso-butyl
    17 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl tert-butyl
    18 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl trifluoromethyl
    19 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl phenyl
    20 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl 4-methylphenyl
    21 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl methyl
    22 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl ethyl
    23 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl propyl
    24 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl iso-propyl
    25 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl butyl
    26 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl iso-butyl
    27 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl tert-butyl
    28 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl trifluoromethyl
    29 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl phenyl
    30 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl naphthanen-2-yl
    31 4-chlorophenyl —NHC(O)NH2 cyclohexyl methyl
    32 4-chlorophenyl —NHC(O)NH2 cyclohexyl ethyl
    33 4-chlorophenyl —NHC(O)NH2 cyclohexyl propyl
    34 4-chlorophenyl —NHC(O)NH2 cyclohexyl iso-propyl
    35 4-chlorophenyl —NHC(O)NH2 cyclohexyl butyl
    36 4-chlorophenyl —NHC(O)NH2 cyclohexyl iso-butyl
    37 4-chlorophenyl —NHC(O)NH2 cyclohexyl tert-butyl
    38 4-chlorophenyl —NHC(O)NH2 cyclohexyl trifluoromethyl
    39 4-chlorophenyl —NHC(O)NH2 cyclohexyl phenyl
    40 4-chlorophenyl —NHC(O)NH2 cyclohexyl naphthanen-2-yl
    41 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl methyl
    42 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl ethyl
    43 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl propyl
    44 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl iso-propyl
    45 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl butyl
    46 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl iso-butyl
    47 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl tert-butyl
    48 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl trifluoromethyl
    49 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl phenyl
    50 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl naphthanen-2-yl
    51 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl methyl
    52 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl ethyl
    53 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl propyl
    54 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl iso-propyl
    55 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl butyl
    56 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl iso-butyl
    57 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl tert-butyl
    58 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl trifluoromethyl
    59 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl phenyl
    60 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl naphthanen-2-yl
  • The following is a scheme for preparing melanocortin receptor ligands of the first aspect of Category 1. For illustrative purposes only, and not by way of limitation, this example utilizes R equal to 4-chlorophenyl, R2 equal to [1,2,4]triazole-1-yl, W1 equal to cyclohexyl, and Q equal to methyl.
    Figure US20050171158A1-20050804-C00054
    • Reagents and Conditions: (a) TFA/CH2Cl2/H2O; rt 1 hr.
  • Figure US20050171158A1-20050804-C00055
    • Reagents and Conditions: (b) HOBt, NMM, EDCI, DMF; rt, 6 hr.
  • Figure US20050171158A1-20050804-C00056
    • Reagents and Conditions: (c) TFA/CH2Cl2/H2O; rt 1 hr.
  • Figure US20050171158A1-20050804-C00057
    • Reagents and Conditions: (d) CH3SO2Cl, TEA, THF; 0° C. to rt, 18 hr. EXAMPLE 1 N-[1-(R)-(4-Chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide (21)
  • Preparation of 4-cyclohexyl-4-[1,2,4]triazole-1-ylmethylpiperidine (18): To a solution of trifluoroacetic acid/dichloromethane/water (1:1:0.1, 10 mL) is added 4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester, 3, (3.5 g, 10 mmol) which was obtained in the procedure herein above and the reaction mixture is allowed to stir for 30 to 60 minutes. The reaction solution is then concentrated in vacuo and partitioned between aqueous NaHCO3 and EtOAc. The organic phase is concentrated in vacuo and the crude product purified by HPLC over silica gel to afford the desired product.
  • Preparation of [1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl] carbamic acid tert-butyl ester (19): To a solution of 4-cyclohexyl-4-[1,2,4]triazole-1-ylmethylpiperidine, 18, (2.16 g, 8.74 mmol), (R)-2-N-(tert-butoxy-carbonyl)-amino-3-(4-chloro)phenyl-propanoic acid [Boc-D-Ph(p-Cl)—OH] (2.65 g, 9.18 mmol), 1-hydroxy-benzotriazole (2.36 g, 17.5 mmol), N-methylmorpholine (35.0 mmol, 3.83 mL) in DMF (30 mL) is added in portions 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.16 g, 11.4 mmol). The reaction is allowed to stir for 6 hours after which it is quenched by adding aqueous NH4Cl. The reaction mixture is extracted with EtOAc and the combined layers are dried, concentrated in vacuo, and the resulting crude product purified over silica gel to afford the desired product.
  • Preparation of 2-(R)-amino-3-(4-chlorophenyl)-1-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)propan-1-one (20): A solution of trifluoroacetic acid/dichloromethane/water (1:1:0.1, 5 mL) is added to [1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl] carbamic acid tert-butyl ester, 19, (3.5 g, 6.65 mmol) and the reaction mixture is allowed to stir for 30 to 60 minutes. The reaction solution is then concentrated in vacuo and partitioned between aqueous NaHCO3 and EtOAc. The organic phase is concentrated in vacuo and the crude product purified via HPLC over silica gel to afford the desired product.
  • Preparation of N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide (21): To a solution of 2-(R)-amino-3-(4-chlorophenyl)-1-(4-cylcohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-propan-1-one, 20, (400 mg, 0.93 mmol) in tetrahydrofuran (10 mL) at 0° C. is added triethylamine (0.78 mL, 5.58 mmol) and methanesulfonyl chloride (0.09 mL, 1.11 mmol). The resulting suspension is allowed to stir at room temperature overnight and the solvent removed under reduced pressure. The crude product is purified by preparative HPLC to afford 314.5 mg (54% yield) of the desired compound as the trifluoroacetic acid salt. 1H NMR (300 MHz, CD3OD) δ 0.80-1.92 (m, 15H), 2.78-3.08 (m, 5H), 3.30-3.90 (m, 4H), 4.25-4.40 (m, 2H), 4.65-4.75 (m, 1H), 7.25-7.40 (m, 4H), 8.00-8.08 (m, 1H), 8.52 (s, 1H). 13C NMR (75 MHz, CD3OD) ppm 27.75, 27.79, 27.85, 27.96, 28.55, 31.08, 31.76, 39.31, 39.41, 40.16, 40.49, 41.89, 42.96, 43.82, 52.61, 53.28, 54.62, 55.29, 130.08, 130.22, 132.81, 132.92, 134.40, 134.58, 136.86, 137.04, 146.62, 151.80, 151.94, 172.50. (rotamers present); 19F NMR (282 MHz, CD3OD) ppm 85.60, 92.52. MS (ESI) m/z 508, (M+H+). Anal. Calcd. for C24H34N5O3ClS 0.30 TFA: C, 54.49; H, 6.37; N, 12.91. Found: C, 54.46; H, 5.93; N, 11.97.
  • Other W1 units which can suitably replace cyclohexyl include, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclopentanone-2-yl, and cycloheptanyl.
  • Non-limiting examples of other analogs of Category I which can be prepared by this process include:
      • N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
      • N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
      • N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
      • N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide;
      • N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-phenylsulfonamide
      • N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-(4-methylphenyl)sulfonamide; and
      • N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-naphthalen-2-ylsulfonamide.
  • The second aspect of Category I melanocortin receptor ligands according to the present invention comprises the 4-cyclohexylpiperidines having the general scaffold with the formula:
    Figure US20050171158A1-20050804-C00058
  • wherein W1 comprises a heterocyclic ring, R, R2, and Q are defined herein below in Table II.
    TABLE II
    No. R R2 W1 Q
    61 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl methyl
    62 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl ethyl
    63 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl propyl
    64 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl iso-propyl
    65 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl butyl
    66 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl iso-butyl
    67 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl tert-butyl
    68 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl trifluoromethyl
    69 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl phenyl
    70 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-1-yl 4-methylphenyl
    71 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl methyl
    72 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl ethyl
    73 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl propyl
    74 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl iso-propyl
    75 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl butyl
    76 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl iso-butyl
    77 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl tert-butyl
    78 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl trifluoromethyl
    79 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl phenyl
    80 4-chlorophenyl 2H-tetrazol-5-yl piperidin-1-yl 4-methylphenyl
    81 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl methyl
    82 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl ethyl
    83 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl propyl
    84 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl iso-propyl
    85 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl butyl
    86 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl iso-butyl
    87 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl tert-butyl
    88 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl trifluoromethyl
    89 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl phenyl
    90 4-chlorophenyl —NHC(═NH)NH2 piperidin-1-yl naphthanen-2-yl
    91 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl methyl
    92 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl ethyl
    93 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl propyl
    94 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl iso-propyl
    95 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl butyl
    96 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl iso-butyl
    97 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl tert-butyl
    98 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl trifluoromethyl
    99 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl phenyl
    100 4-chlorophenyl —NHC(O)NH2 piperidin-1-yl naphthanen-2-yl
    101 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl methyl
    102 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl ethyl
    103 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl propyl
    104 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl iso-propyl
    105 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl butyl
    106 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl iso-butyl
    107 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-y1 tert-butyl
    108 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl trifluoromethyl
    109 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl phenyl
    110 4-chlorophenyl —NHC(═NCH3)NH2 piperidin-1-yl naphthanen-2-yl
    111 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl methyl
    112 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl ethyl
    113 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl propyl
    114 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl iso-propyl
    115 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl butyl
    116 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl iso-butyl
    117 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl tert-butyl
    118 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl trifluoromethyl
    119 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl phenyl
    120 4-chlorophenyl —NHC(═NCN)NHNO2 piperidin-1-yl naphthanen-2-yl
  • The following is a scheme for preparing melanocortin receptor ligands of the first aspect of Category I. For illustrative purposes only, and not by way of limitation, this example utilizes R equal to 4-chlorophenyl, R2 equal to [1,2,4]triazole-1-yl, W1 equal to piperidin-4-yl, and Q equal to methyl.
    Figure US20050171158A1-20050804-C00059
    • Reagents and Conditions: (a) Na, propanol; Reflux 72 hr.
  • Figure US20050171158A1-20050804-C00060
    • Reagents and Conditions: (b) HOBt, NMM, EDCI, DMF, DIPEA; 0° C. to rt, 18 hr.
  • Figure US20050171158A1-20050804-C00061
    • Reagents and Conditions: (c) CH3SO2Cl, TEA, CH2Cl2; 0° C. to rt, 18 hr.
  • Figure US20050171158A1-20050804-C00062
    • Reagents and Conditions: (d) sodium[1,2,4]triazole, DMF; 55° C., 18 hr. EXAMPLE 2 N-[1-(R)-(4-Chlorobenzyl)-2-oxo-2-(4′-[1,2,4]triazole-1-ylmethyl-[1,4′]bipiperidinyl-1′-yl)-ethyl]-methanesulfonamide (26)
  • Preparation of [1,4′]bipiperidinyl-4′-ylmethanol (22): In a three neck round-bottom flask equipped with a stirring bar, reflux condenser, and rubber septa is placed [1,4′]bipiperidinyl-4′-carboxylic acid amide (5.01 g, 23.7 mmol) in 140 mL of anhydrous 1-propanol and the solution is heated to reflux. Sodium metal (˜9.276 g, 403.4 mmol) rinsed in hexane to remove mineral oil) is added in portions. Once the sodium metal completely dissolves, the mixture is allowed to stir over the weekend. The reaction mixture is cooled to room temperature and the solvent removed under reduced pressure. Distilled water is added and the solution extracted with chloroform. The organic layer is collected, dried over sodium sulfate, filtered, and the solvent removed under reduced pressure to afford 4.4 g of the desired product which is used without further purification. 1H NMR (CD3OD, 300 MHz) δ 1.48-1.60 (m, 8H), 1.72-1.80 (m, 2H), 2.61-2.71 (m, 6H), 2.92-3.01 (m, 2H), 3.37 (s, 1H), 3.56 (s, 2H). MS (ESI) m/z 199 (M+H+).
  • Preparation of [1-(R)-(4-chlorobenzyl)-2-(4′-hydroxymethyl-[1,4′]-bipiperidinyl-1′-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester (23): To a round bottom flask equipped with a stirring bar is charged [1,4′]bipiperidinyl-4′-yl-methanol, 22, (2.2 g, 11.1 mmol, 1.0 eq.) 2-(R)-tert-butoxycarbonylamino-3-(4-chlorophenyl)-propionic acid (3.648 g, 12.2 mmol), 1-hydroxybenzotriazole (2.552 g, 18.9 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (3.71 g, 18.9 mmol) in anhydrous N,N-dimethylformamide (80 mL). The mixture is cooled to 0° C. and N,N-diisopropyl-ethylamine (4.1 mL, 37.7 mmol) is added. The ice bath is removed and the reaction mixture allowed to stir overnight. The mixture is concentrated under reduced pressure and purified by preparative HPLC to afford 2.83 g (43% yield) of the desired compound as the trifluoroacetic acid salt. 1H NMR (CD3OD, 300 MHz) δ 0.85-2.13 (m, 19H), 2.65-3.82 (m, 8H), 3.90-4.10 (m, 3H), 4.48 (m, 1H), 4.76 (m, 1H), 7.22-7.48 (m, 4H). MS (ESI) m/z 480 (M+H+).
  • Preparation of 3-[3-(4-Chloro-phenyl)-2-R-methanesulfonylamino-propionyl]-3-aza-7-azonia-dispiro[5.0.5.1]tridecane chloride (25): To a cooled (0° C.) solution of [1-(R)-(4-chloro-benzyl)-2-(4′-hydroxymethyl-[1,4′]bipiperidinyl-1′-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester, 23, (500 mg, 0.84 mmol, 1.0 eq.) in dichloromethane (15 mL) is added triethylamine (0.24 mL, 1.7 mmol) and methanesulfonyl chloride (0.13 mL, 1.7 mmol). The ice bath is removed and the solution allowed to warm to room temperature and continue stirring overnight. The next morning water is added and the reaction mixture extracted with dichloromethane. The organic layer is collected, dried over sodium sulfate, filtered and the solvent was removed under reduced pressure. The resulting crude product is a mixture of the desired product and 3-[2-(R)-tert-butoxy-carbonylamino-3-(4-chloro-phenyl)-propionyl]-3-aza-7-azonia-dispiro[5.0.5.1 ]tridecane chloride, 24. The crude products are separated by preparative HPLC to afford 121.6 mg (30% yield) of the desired product and 231.9 mg (56% yield) of the major by product, 24. Desired product: 1H NMR (CD3OD, 300 MHz) δ 1.48-2.18 (m, 10H), 2.72-3.63 (m, 13H), 3.97 (m, 1H), 4.48 (m, 1H), 4.70 (m, 1H), 7.28-7.42 (m, 4H). MS (ESI) m/z 475 (M+H+). By-product, 24: 1H NMR (CD3OD, 300 MHz) δ 1.32-2.15 (m, 19H), 2.86-3.72 (m, 10H), 3.95 (m, 1H), 4.78 (m, 1H), 4.78 (m, 1H), 7.23-7.48 (m, 4H). MS (ESI) m/z 498 (M+H+).
  • Preparation of N-[1-(R)-(4-chloro-benzyl)-2-oxo-2-(4′-[1,2,4]triazol-1-ylmethyl-[1,4′]bipiperidinyl-1′-yl)-ethyl]-methanesulfonamide (26): To a solution of 3-[3-(4-chloro-phenyl)-2-R-methanesulfonylamino-propionyl]-3-aza-7-azonia-dispiro[5.0.5.1]tridecane chloride, 25, (121.6 mg, 0.26 mmol) in anhydrous N,N-dimethylformamide (15 mL) is added 1,2,4-triazole, sodium derivative (91.0 mg, 1.0 mmol). The solution is heated to 55° C. and allowed to stir overnight. The next morning the solution is cooled to room temperature, the solvent removed under reduced pressure and the crude material purified by preparative HPLC to afford 81.9 mg (43% yield) of the desired compound as the bis-trifluoroacetic acid salt. 1H NMR (CD3OD, 300 MHz) δ 1.17-2.35 (m, 10H), 2.79-4.00 (m, 11H), 4.20 (m, 1H), 4.47-4.74 (m, 2H), 5.00 (m, 2H), 7.25-7.46 (m, 4H), 8.19 (s, 1H), 8.68 (m, 1H). MS (ESI) m/z 509 (M+H+). 13C NMR (CD3OD, 300 MHz) δ 15.50, 22.88, 25.16, 25.34, 29.10, 29.82, 38.64, 39.18, 39.68, 41.55, 41.63, 42.19, 42.53, 54.39, 54,60, 66.89, 68,54, 129.69, 129.88, 132.37, 132.69, 132.80, 133.97, 134.09, 136.58, 136.75, 147.44, 153.07, 153.53, 153.66, 162.35, 162.60, 171.95.
  • Other units which are suitable for W1 under aspect 2 of Category II analogs include: phenyl, pyridin-4-yl, piperidin-4-yl, morpholin-4-yl, pyrazin-1-yl, pyran-4-yl, and the like.
  • The third aspect of Category I melanocortin receptor ligands according to the present invention comprises the 4-cyclohexylpiperidines having the general scaffold with the formula:
    Figure US20050171158A1-20050804-C00063
  • wherein W1 comprises a heterocyclic ring, R, R2, and Q are defined herein below in Table III.
    TABLE III
    No. R R2 W1 Q
    121 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl methyl
    122 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl ethyl
    123 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl propyl
    124 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl iso-propyl
    125 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl butyl
    126 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl iso-butyl
    127 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl tert-butyl
    128 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl trifluoromethyl
    129 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl phenyl
    130 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl 4-methylphenyl
    131 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl methyl
    132 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl ethyl
    133 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl propyl
    134 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl iso-propyl
    135 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl butyl
    136 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl iso-butyl
    137 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl tert-butyl
    138 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl trifluoromethyl
    139 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl phenyl
    140 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl 4-methylphenyl
    141 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl methyl
    142 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl ethyl
    143 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl propyl
    144 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl iso-propyl
    145 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl butyl
    146 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl iso-butyl
    147 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl tert-butyl
    148 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl trifluoromethyl
    149 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl phenyl
    150 4-chlorophenyl —NHC(═NH)NH2 cyclohexyl naphthanen-2-yl
    151 4-chlorophenyl —NHC(O)NH2 cyclohexyl methyl
    152 4-chlorophenyl —NHC(O)NH2 cyclohexyl ethyl
    153 4-chlorophenyl —NHC(O)NH2 cyclohexyl propyl
    154 4-chlorophenyl —NHC(O)NH2 cyclohexyl iso-propyl
    155 4-chlorophenyl —NHC(O)NH2 cyclohexyl butyl
    156 4-chlorophenyl —NHC(O)NH2 cyclohexyl iso-butyl
    157 4-chlorophenyl —NHC(O)NH2 cyclohexyl tert-butyl
    158 4-chlorophenyl —NHC(O)NH2 cyclohexyl trifluoromethyl
    159 4-chlorophenyl —NHC(O)NH2 cyclohexyl phenyl
    160 4-chlorophenyl —NHC(O)NH2 cyclohexyl naphthanen-2-yl
    161 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl methyl
    162 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl ethyl
    163 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl propyl
    164 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl iso-propyl
    165 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl butyl
    166 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl iso-butyl
    167 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl tert-butyl
    168 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl trifluoromethyl
    169 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl phenyl
    170 4-chlorophenyl —NHC(═NCH3)NH2 cyclohexyl naphthanen-2-yl
    171 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl methyl
    172 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl ethyl
    173 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl propyl
    174 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl iso-propyl
    175 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl butyl
    176 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl iso-butyl
    177 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl tert-butyl
    178 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl trifluoromethyl
    179 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl phenyl
    180 4-chlorophenyl —NHC(═NCN)NHNO2 cyclohexyl naphthanen-2-yl
  • The following is a scheme for preparing melanocortin receptor ligands of the third aspect of Category I. For illustrative purposes only, and not by way of limitation, this example utilizes R equal to 4-chlorophenyl, R2 equal to guanidinyl, W1 equal to cyclohexyl, and Q equal to methyl. The procedure herein below begins with intermediate, 17.
    Figure US20050171158A1-20050804-C00064
    • Reagents and Conditions (a) HOBt, NMM, EDCI, DMF; rt 6 hr.
  • Figure US20050171158A1-20050804-C00065
    • Reagents and Conditions (b) TFA/CH2Cl2/H2O; rt 1 hr.
  • Figure US20050171158A1-20050804-C00066
    Figure US20050171158A1-20050804-C00067
    • EXAMPLE 3 N-[1-(R)-(4-Chlorobenzyl)-2-(4-cyclohexyl-4-guanidinylpropyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide (30)
  • Preparation of {1-(R)-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(4-N′,N″-dicarbobenzyloxypropyl)-piperidin-1-yl]-2-oxo-ethyl } carbamic acid tert-butyl ester (27): To a solution of N-[3-(4-cyclohexyl-piperidin-4-yl)-propyl]-dicarbobenzyloxy-guanidine, 17, (4.67 g, 8.74 mmol), (R)-2-N-(tert-butoxy-carbonyl)-amino-3-(4-chloro)phenyl-propanoic acid [Boc-D-Ph(p-Cl)—OH] (2.65 g, 9.18 mmol), 1-hydroxybenzotriazole (2.36 g, 17.5 mmol), N-methylmorpholine (35.0 mmol, 3.83 mL) in DMF (30 mL) is added in portions 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.16 g, 11.4 mmol). The reaction is allowed to stir for 6 hours after which it is quenched by adding aqueous NH4Cl. The reaction mixture is extracted with EtOAc and the combined layers are dried, concentrated in vacuo, and the resulting crude product purified over silica gel to afford the desired product.
  • Preparation of 2-(R)-amino-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(N′,N″-dicarbobenzyloxyguanidinylpropyl)-piperidin-1-yl]-propan-1-one (28): A solution of trifluoroacetic acid/dichloromethane/water (1:1:0.1, 5 mL) is added to {1-(R)-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(4-N′,N″-dicarbobenzyloxyguanidinylpropyl)-piperidin-1-yl]-2-oxo-ethyl} carbamic acid tert-butyl ester, 27, (5.43 g, 6.65 mmol) and the reaction mixture is allowed to stir for 30 to 60 minutes. The reaction solution is then concentrated in vacuo and partitioned between aqueous NaHCO3 and EtOAc. The organic phase is concentrated in vacuo and the crude product purified via HPLC over silica gel to afford the desired product.
  • Preparation of N-{1-(R)-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(N′,N″-dicarbobenzyloxyguanidinylpropyl]-piperidin-1-yl)-2-oxo-ethyl}-methane-sulfonamide (29): To a solution of 2-(R)-amino-3-(4-chlorophenyl)-1-(4-cylcohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-propan-1-one, 28, (666 mg, 0.93 mmol) in tetrahydrofuran (10 mL) at 0° C. is added triethylamine (0.78 mL, 5.58 mmol) and methanesulfonyl chloride (0.09 mL, 1.11 mmol). The resulting suspension is allowed to stir at room temperature overnight and the solvent removed under reduced pressure. The crude product is purified by preparative HPLC to afford the desired compound.
  • Preparation of N-[1-(R)-(4-Chlorobenzyl)-2-(4-cyclohexyl-4-guanidinylpropyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide (30): To a solution of N-{1-(R)-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(N′,N″-dicarbobenzyloxyguanidinylpropyl]-piperidin-1-yl)-2-oxo-ethyl}-methane-sulfonamide, 29, (100 mg) in methanol (3 mL) is added 10% palladium on carbon (12 mg) under argon. The mixture is purged with a hydrogen flow and then stirred for two hours under a hydrogen atmosphere at atmospheric pressure. The reaction mixture is then filtered through a short pad of Celite, and the filtrate concentrated under reduced pressure. The crude product is purified by preparative HPLC to afford desired compound as the trifluoroacetic acid salt.
  • The following precursors can be used to prepare the melanocortin receptor ligands which comprise Category II of the present invention. These precursors can be combined with the precursors which are utilized in preparing the 4,4-disubstituted piperidine scaffolds which comprise Category I described herein above.
  • A first precursor useful in preparing melanocortin receptor ligands relates to the 3-(4-chlorophenyl)propionic acid derivatives available via the scheme outlined below.
    Figure US20050171158A1-20050804-C00068
    Figure US20050171158A1-20050804-C00069
    Figure US20050171158A1-20050804-C00070
    Figure US20050171158A1-20050804-C00071
  • Preparation of 3-(4-chlorophenyl)propionyl chloride (31): To a solution of 3-(4-chloro-phenyl)-propionic acid (1.5 g, 8.15 mmol) in benzene (50 mL) is added thionyl chloride (1.18 mL, 16.3 mmol). The resulting solution is heated to reflux for twenty-four hours and then cooled to room temperature. The solvents are removed under reduced pressure to afford 1.45 g (88% yield) of the desired compound as a colorless oil. The crude product is used without further purification. 1H NMR (CDCl3 300 MHz) δ 3.01 (t, J=7.2 Hz, 2H), 3.22 (t, J=6.9 Hz, 2H), 7.12-7.20 (m, 2H), 7.26-7.35 (m, 2H).
  • Preparation of 3-[3-(4-chloro-phenyl)-propionyl]-4-(R)-methyl-5-(S)-phenyl-oxazolidin-2-one (32): To a cooled (−78° C.) solution of 4-(R)-methyl-5-(S)-phenyl-oxazolidin-2-one, 31, (600 mg, 3.39 mmol) in anhydrous tetrahydrofuran (20 mL) is added n-butyl lithium (2.5 mL, 1.6M solution in hexanes, 4.07 mmol). The resulting solution is stirred at −78° C. for ninety minutes and then 3-(4-chloro-phenyl)-propionyl chloride (894 mg, 4.41 mmol) is slowly added. The solution is warmed to room temperature for thirty minutes and then the solvents removed under reduced pressure. The crude product is purified over silica (20:80 ethyl acetate:hexanes, Rf˜0.3) to afford 1.07 g (92% yield) of the desired compound as a colorless solid. 1H NMR (CDCl3 300 MHz) δ 0.91 (d, J=6.6 Hz, 3H), 3.01 (t, J=7.8 Hz, 2H), 3.18-3.40 (m, 2H), 4.77 (m, 1H), 5.67 (d, J=7.2 Hz, 1H), 7.18-7.48 (m, 9H). MS (ESI) m/z 344 (M+H+)
  • Preparation of 3-[2-(S)-(4-chloro-benzyl)-5-methyl-hex-4-enoyl]-4-(R)-methy-5-(S)-phenyl-oxazolidin-2-one (33): To a cooled (−78° C.) solution of 3-[3-(4-chloro-phenyl)-propionyl]-4-(R)-methyl-5-(S)-phenyl-oxazolidin-2-one, 32, (500 mg, 1.46 mmol) in THF (15 mL) is added sodium bis(trimethylsilyl)-amide (1.75 mL, 1.0M solution in THF, 1.75 mmol). The resulting solution is stirred at −78° C. then 4-bromo-2-methyl-2-butene (0.20 mL, 1.75 mmol) is slowly added. The resulting solution is stirred at room temperature overnight, and the solvent removed under reduced pressure. The crude product is purified by preparative HPLC to afford 213 mg (36% yield) of the desired compound as a colorless oil. 1H NMR (CDCl3 300 MHz) δ 0.83 (d, J=6.6 Hz, 3H), 1.62 (s, 3H), 1.70 (s, 3H), 2.20-2.55 (m, 2H), 2.77-3.10 (m, 2H), 4.20-4.35 (m, 1H), 4.55-4.68 (m, 1H), 5.15-5.25 (m, 1H), 5.38 (d, J=7.2 Hz, 1H), 7.15-7.45 (m, 9H). MS (ESI) m/z 412 (M+H+)
  • Preparation of (S)-2-(4-Chloro-benzyl)-5-methyl-hex-4-enoic acid (34): To a cooled solution of 3-[2-S-(4-chloro-benzyl)-5-methyl-hex-4-enoyl]-4-R-methy-5-S-phenyl-oxazolidin-2-one, 33, (1 mmol) in THF (5 mL) is added a mixture of LiOH/30% H2O2 (1.5 mmol of each) at 0° C. The reaction is stirred for 1 hr, then quenched with 1N HCl (pH˜2). The solvent is removed, and the product purified over silica to provide the desired product as a white solid.
  • Using the above procedures and modifications thereof, the following precursors 35-40 can also be suitably prepared.
    Figure US20050171158A1-20050804-C00072
  • The first aspect of Category II melanocortin receptor ligands according to the present invention comprises the 4-cyclohexylpiperidines having the general scaffold with the formula:
    Figure US20050171158A1-20050804-C00073
  • wherein R, R2, R4a, R4b, Q, and the index j are defined herein below in Table IV.
    TABLE IV
    No. R R2 R4a R4b j Q
    181 4-fluorophenyl [1,2,4]triazol-1-yl H H 1 phenyl
    182 4-fluorophenyl [1,2,4]triazol-1-yl H —CH3 1 phenyl
    183 4-fluorophenyl [1,2,4]triazol-1-yl H —NH2 1 phenyl
    184 4-fluorophenyl [1,2,4]triazol-1-yl H —NHCH3 1 phenyl
    185 4-fluorophenyl [1,2,4]triazol-1-yl H —NHC(O)CH3 1 phenyl
    186 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 H 1 phenyl
    187 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 —CH3 1 phenyl
    188 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 —NH2 1 phenyl
    189 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 —NHCH3 1 phenyl
    190 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 —NHC(O)CH3 1 phenyl
    191 4-fluorophenyl [1,2,4]triazol-1-yl H H 1 4-OH-phenyl
    192 4-fluorophenyl [1,2,4]triazol-1-yl H —CH3 1 4-OH-phenyl
    193 4-fluorophenyl [1,2,4]triazol-1-yl H —NH2 1 4-OH-phenyl
    194 4-fluorophenyl [1,2,4]triazol-1-yl H —NHCH3 1 4-OH-phenyl
    195 4-fluorophenyl [1,2,4]triazol-1-yl H —NHC(O)CH3 1 4-OH-phenyl
    196 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 H 1 4-OH-phenyl
    197 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 —CH3 1 4-OH-phenyl
    198 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 —NH2 1 4-OH-phenyl
    199 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 —NHCH3 1 4-OH-phenyl
    200 4-fluorophenyl [1,2,4]triazol-1-yl —CH3 —NHC(O)CH3 1 4-OH-phenyl
    201 4-chlorophenyl [1,2,4]triazol-1-yl H H 1 phenyl
    202 4-chlorophenyl [1,2,4]triazol-1-yl H —CH3 1 phenyl
    203 4-chlorophenyl [1,2,4]triazol-1-yl H —NH2 1 phenyl
    204 4-chlorophenyl [1,2,4]triazol-1-yl H —NHCH3 1 phenyl
    205 4-chlorophenyl [1,2,4]triazol-1-yl H —NHC(O)CH3 1 phenyl
    206 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 H 1 phenyl
    207 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 —CH3 1 phenyl
    208 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 —NH2 1 phenyl
    209 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 —NHCH3 1 phenyl
    210 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 —NHC(O)CH3 1 phenyl
    211 4-chlorophenyl [1,2,4]triazol-1-yl H H 1 4-OH-phenyl
    212 4-chlorophenyl [1,2,4]triazol-1-yl H —CH3 1 4-OH-phenyl
    213 4-chlorophenyl [1,2,4]triazol-1-yl H —NH2 1 4-OH-phenyl
    214 4-chlorophenyl [1,2,4]triazol-1-yl H —NHCH3 1 4-OH-phenyl
    215 4-chlorophenyl [1,2,4]triazol-1-yl H —NHC(O)CH3 1 4-OH-phenyl
    216 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 H 1 4-OH-phenyl
    217 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 —CH3 1 4-OH-phenyl
    218 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 —NH2 1 4-OH-phenyl
    219 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 —NHCH3 1 4-OH-phenyl
    220 4-chlorophenyl [1,2,4]triazol-1-yl —CH3 —NHC(O)CH3 1 4-OH-phenyl
    221 4-fluorophenyl imidazol-1-yl H H 1 phenyl
    222 4-fluorophenyl imidazol-1-yl H —CH3 1 phenyl
    223 4-fluorophenyl imidazol-1-yl H —NH2 1 phenyl
    224 4-fluorophenyl imidazol-1-yl H —NHCH3 1 phenyl
    225 4-fluorophenyl imidazol-1-yl H —NHC(O)CH3 1 phenyl
    226 4-fluorophenyl imidazol-1-yl —CH3 H 1 phenyl
    227 4-fluorophenyl imidazol-1-yl —CH3 —CH3 1 phenyl
    228 4-fluorophenyl imidazol-1-yl —CH3 —NH2 1 phenyl
    229 4-fluorophenyl imidazol-1-yl —CH3 —NHCH3 1 phenyl
    230 4-fluorophenyl imidazol-1-yl —CH3 —NHC(O)CH3 1 phenyl
    231 4-fluorophenyl imidazol-1-yl H H 1 4-OH-phenyl
    232 4-fluorophenyl imidazol-1-yl H —CH3 1 4-OH-phenyl
    233 4-fluorophenyl imidazol-1-yl H —NH2 1 4-OH-phenyl
    234 4-fluorophenyl imidazol-1-yl H —NHCH3 1 4-OH-phenyl
    235 4-fluorophenyl imidazol-1-yl H —NHC(O)CH3 1 4-OH-phenyl
    236 4-fluorophenyl imidazol-1-yl —CH3 H 1 4-OH-phenyl
    237 4-fluorophenyl imidazol-1-yl —CH3 —CH3 1 4-OH-phenyl
    238 4-fluorophenyl imidazol-1-yl —CH3 —NH2 1 4-OH-phenyl
    239 4-fluorophenyl imidazol-1-yl —CH3 —NHCH3 1 4-OH-phenyl
    240 4-fluorophenyl imidazol-1-yl —CH3 —NHC(O)CH3 1 4-OH-phenyl
    241 4-chlorophenyl imidazol-1-yl H H 1 phenyl
    242 4-chlorophenyl imidazol-1-yl H —CH3 1 phenyl
    243 4-chlorophenyl imidazol-1-yl H —NH2 1 phenyl
    244 4-chlorophenyl imidazol-1-yl H —NHCH3 1 phenyl
    245 4-chlorophenyl imidazol-1-yl H —NHC(O)CH3 1 phenyl
    246 4-chlorophenyl imidazol-1-yl —CH3 H 1 phenyl
    247 4-chlorophenyl imidazol-1-yl —CH3 —CH3 1 phenyl
    248 4-chlorophenyl imidazol-1-yl —CH3 —NH2 1 phenyl
    249 4-chlorophenyl imidazol-1-yl —CH3 —NHCH3 1 phenyl
    250 4-chlorophenyl imidazol-1-yl —CH3 —NHC(O)CH3 1 phenyl
    251 4-chlorophenyl imidazol-1-yl H H 1 4-OH-phenyl
    252 4-chlorophenyl imidazol-1-yl H —CH3 1 4-OH-phenyl
    253 4-chlorophenyl imidazol-1-yl H —NH2 1 4-OH-phenyl
    254 4-chlorophenyl imidazol-1-yl H —NHCH3 1 4-OH-phenyl
    255 4-chlorophenyl imidazol-1-yl H —NHC(O)CH3 1 4-OH-phenyl
    256 4-chlorophenyl imidazol-1-yl —CH3 H 1 4-OH-phenyl
    257 4-chlorophenyl imidazol-1-yl —CH3 —CH3 1 4-OH-phenyl
    258 4-chlorophenyl imidazol-1-yl —CH3 —NH2 1 4-OH-phenyl
    259 4-chlorophenyl imidazol-1-yl —CH3 —NHCH3 1 4-OH-phenyl
    260 4-chlorophenyl imidazol-1-yl —CH3 —NHC(O)CH3 1 4-OH-phenyl
  • The following is a scheme for preparing melanocortin receptor ligands of the first aspect of Category II. For illustrative purposes only, and not by way of limitation, this example utilizes R equal to 4-fluorophenyl, R2 equal to [1,2,4]triazole-1-yl, W1 equal to cyclohexyl, and Q equal to 4-hydroxyphenyl. The procedure herein below utilizes intermediate 18 for the convergent step wherein the 4,4-substituted piperidine is reacted with the balance of the final compound scaffold.
    Figure US20050171158A1-20050804-C00074
    Figure US20050171158A1-20050804-C00075
    Figure US20050171158A1-20050804-C00076
    Figure US20050171158A1-20050804-C00077
    Figure US20050171158A1-20050804-C00078
    Figure US20050171158A1-20050804-C00079
    Figure US20050171158A1-20050804-C00080
    Figure US20050171158A1-20050804-C00081
    Figure US20050171158A1-20050804-C00082
    Figure US20050171158A1-20050804-C00083
    Figure US20050171158A1-20050804-C00084
    Figure US20050171158A1-20050804-C00085
    Figure US20050171158A1-20050804-C00086
    • EXAMPLE 4 N-[5-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-4-R-(4-fluoro-benzyl)-(4-hydroxy-benzyl)-5-oxo-pentyl]-acetamide (53)
  • Preparation of methanesulfonic acid 3-(4-benzyloxy-phenyl)-2-S-tert-butoxycarbonylamino-propyl ester (41): To a cooled (0° C.) solution of [2-(4-benzyloxy-phenyl)-1-S-hydroxymethyl-ethyl]-carbamic acid tert-butyl ester (102.3 g, 286.2 mmol), triethylamine (126 mL, 90.4 mmol) in methylene chloride (2000 mL) is added methanesulfonic anhydride (55.4 g, 31.8 mmol) in three portions over one hour. After the addition is complete, the resulting solution is stirred at 0° C. for thirty minutes and then allowed to warm to room temperature over ninety minutes. The solution is again cooled to 0° C. and quenched with ice-cold 1N aqueous hydrochloric acid (1996 mL) and then stirred vigorously at 0° C. for fifteen minutes. The aqueous layer is removed and extracted with methylene chloride (500 mL). The combined organics are washed with brine (500 mL), dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to provide a thick slurry which is diluted with hexanes (300 mL). The resulting solid that forms is collected by filtration, washed with hexanes (50 mL) and dried to constant weight in vacuo to afford 119.6 g (96% yield) of the desired compound which is used without further purification.
  • Preparation of [1-(4-benzyloxy-benzyl)-2-cyano-ethyl]-carbamic acid tert-butyl ester (42): To a solution of methanesulfonic acid 3-(4-benzyloxy-phenyl)-2-S-tert-butoxycarbonylamino-propyl ester, 41, (119.5 g, 274.5 mmol), in N,N-dimethylformamide (1020 mL) is added sodium cyanide (30.0 g, 612 mmol). The resulting suspension is heated to 60° C. for eighteen hours and then cooled to room temperature. The reaction is diluted with water (4400 mL) and extracted with ethyl acetate (3×2400 mL). The combined organic extracts are washed successively with water (2×2000 mL) and saturated aqueous sodium chloride (2000 mL). The organics layers are separated, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified over silica (2:3 ethyl acetate:hexanes) to afford 75.1 g (77.7% yield) of the desired compound as a solid.
  • Preparation of 3-S-amino-4-(4-benzyloxy-phenyl)-butyric acid (43): To a suspension of [1-(4-benzyloxy-benzyl)-2-cyano-ethyl]-carbamic acid tert-butyl ester, 42, (52.0 g, 142 mmol) in methanol (1500 mL) is heated to 45° C. and then water (156 mL and 50% aqueous sodium hydroxide (312 mL 5960 mmol) is added. The resulting solution is heated to 75° C. for five hours and then cooled to room temperature. The methanol is removed under reduced pressure and the residue diluted with water (1200 mL) and subsequently heated to 90° C. Hydrogen peroxide (87 mL, 50 wt. % solution in water, 1500 mmol) is then added over forty minutes and the resulting solution heated at 95° C. for an additional eighteen hours. Additional hydrogen peroxide (40 mL 690 mmol) is added and the mixture heated to reflux for five hours followed by cooling to 40° C. The reaction mixture is poured over ice (8000 mL) and then acidified to pH 2.1 with ice-cold 2 M sulfuric acid. The resulting suspension is vigorously stirred for fifteen minutes and the resulting solid collected by filtration. The solid is washed with water (2×500 mL) and dried to constant weight in vacuo. The crude product is used without further purification.
  • Preparation of 4-(4-benzyloxyphenyl)-3-S-tert-butoxycarbonylamino-butyric acid (44): To a solution of 3-S-amino-4-(4-benzyloxy-phenyl)-butyric acid, 43, (40.47 g, 142 mmol) in 1,4-dioxane (1500 mL) is added triethylamine (108.8 mL, 780.6 mmol) water (1500 mL) and sodium hydrogen carbonate (23.6 g, 281 mmol). The resulting suspension was stirred at room temperature for two hours to give a complete solution. The solution is then cooled to 0° C. and a solution of di-tert-butyl dicarbonate (53.3 g, 244 mmol) in 1,4-dioxane (300 mL) is added dropwise over thirty minutes. After the addition is complete the solution is stirred at 0° C. for one hour and then allowed to warm to room temperature for eighteen hours. The organic solvent is removed under reduced pressure and the aqueous layer partitioned between water (1000 mL) and ethyl acetate (1000 mL). The mixture is cooled to 0° C. and then acidified to pH 2.1 by the slow addition of aqueous 1M potassium hydrogen sulfate (˜760 mL). The aqueous layer is removed and extracted with ethyl acetate (2×500 mL). The combined organic layers are washed with saturated aqueous sodium chloride (2×750 mL), dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to a residue which is then triterated with ether (400 mL). The mixture is diluted with hexanes (400 mL) and concentrated under reduced pressure to a thick slurry. The resulting solid is collected by filtration, rinsed with hexanes (2×100 mL) and dried to a constant weight in vacuo to give 49.2 g (90% yield) of the desired compound which is used without further purification.
  • Preparation of [1-S-(4-benzyloxy-benzyl)-3-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-3-oxo-propyl]-carbamic acid tert-butyl ester (45): To a cooled (−1° C.) solution of 4-(4-benzyloxyphenyl)-3-S-tert-butoxycarbonylamino-butyric acid, 44, (96.4 g, 251 mmol) in niethylene chloride (2500 mL) is added 4-dimethylaminopyridine (45.8 g, 375 mmol), 2,2-dimethyl-1,3-dioxan-4,6-dione (39.9 g, 277 mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (72.5 g, 378 mmol). The resulting solution is stirred at −1° C. for ninety minutes and then warmed to room temperature overnight. The reaction is diluted with methylene chloride (1000 mL), cooled to 0° C., and washed successively with ice-cold 1M potassium hydrogen sulfate (3×700 mL), water (1000 mL) and saturated aqueous sodium chloride (1000 mL). The organics were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to a yellow residue. The residue is dissolved in a 1:1 mixture of methylene chloride/ether (300 mL), diluted with hexanes (150 mL), and then concentrated under reduced pressure to a thick slurry. The resulting solid is collected by filtration, rinsed with ethyl ether (100 mL) and dried to constant weight in vacuo to afford 120.0 g (94% yield) of the desired compound which is used without further purification.
  • Preparation of [1-R-(4-benzyloxy-benzyl)-3-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-propyl]-carbamic acid tert-butyl ester (46): To a cooled (0° C.) solution of [1-S-(4-benzyloxy-benzyl)-3-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-3-oxo-propyl]-carbamic acid tert-butyl ester, 45, (120.9 g, 236.3 mmol) in methylene chloride (2300 mL) is added acetic acid (150 mL, 2620 mmol) and sodium borohydride (35.9 g, 949 mmol) in portions over forty-five minutes. After the addition is complete the mixture is stirred at 0° C. for ninety minutes and then allowed to warm to room temperature overnight. The reaction is quenched by the slow addition of water (1000 mL) and then the aqueous layer is removed and extracted with methylene chloride (2×750 mL). The combined organics are washed successively with water (2×1000 mL) and saturated aqueous sodium chloride (3×1000 mL), dried over anhydrous magnesium sulfate filtered, and then concentrated under reduced pressure. The crude product is purified by chromatography on silica gel (methylene chloride-methylene chloride:ethyl acetate, 3:1-2:1). The pure fractions are collected and concentrated under reduced pressure to a residue. The residue is triturated with methylene chloride (400 mL) and then concentrated at 0° C. to a thick slurry. The solid is collected by filtration, washed with 1:1 ethyl ether:hexanes (2×75 mL) and then dried to constant weight in vacuo to give 46.8 g (50% yield of the desired compound.
  • Preparation of 2-R-(4-benzyloxy-benzyl)-6-oxo-piperidine-1-carboxylic acid tert-butyl ester (47): To a suspension of [1-R-(4-benzyloxy-benzyl)-3-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-propyl]-carbamic acid tert-butyl ester, 46, (38.5 g, 77.4 mmol) in xylenes (750 mL) was heated to reflux for two hours until the solid was completely in solution and was then cooled to 60° C. Di-tert-butyl dicarbonate (11.5 g, 52.7 mmol) and 4-(dimethyl-amino)pyridine (4.0 g, 33 mmol) were added and the resulting solution was stirred at 60° C. for two hours and then cooled to 3° C. The solution was washed successively with ice-cold 1M potassium hydrogen sulfate (230 mL), water (200 mL), saturated aqueous sodium bicarbonate (200 mL) and saturated aqueous sodium chloride (100 mL). The organics were dried over anhydrous sodium sulfate, filtered and then concentrated under reduced pressure to a pale yellow residue. The crude product was purified by chromatography on silica gel (methylene chloride:ethyl acetate 4:1-3:1) and the pure fractions were collected and concentrated under reduced pressure. The residue was dissolved in ethyl ether (200 mL) and the resulting solution was diluted with hexanes (100 mL) and then concentrated at 0° C. in vacuo to a thick slurry. The solid was collected by filtration and rinsed with 5% ethyl ether in hexanes (100 mL) and then dried to constant weight in vacuo to give 26.5 g (87% yield) of the desired compound. 1H NMR (500 MHz) 1.52 (s, 9H), 1.65-1.80 (m, 3H), 1.90-2.05 (m, 1H), 2.45-2.58 (m, (m, 2H), 2.60-2.70 (m, 1H), 3.00-3.08 (m, 1H), 4.35-4.40 (m, 1H), 5.05 (s, 2H), 6.93 (d, 2H), 7.13 (d, 2H), 7.28-7.35 (m, 1H), 7.35-7.50 (m, 4H). 13C NMR (125 MHz) 17.11, 24.69, 28.19, 34.53, 39.14, 57.40, 70.23, 83.06, 115.18, 127.56, 128.07, 128.70, 130.29, 130.40, 137.20, 152.98, 157.80, 171.62. MS (ESI) m/z 418 (M+Na+). Anal Calcd. for C24H29NO4: C, 72.89; H, 7.39; N, 3.54. Found: C,72.97; H, 7.44; 3.53.
  • Preparation of 6-R-(4-Benzyloxy-benzyl)-3-R-(4-fluoro-benzyl)-2-oxo-piperidine-1-carboxylic acid tert-butyl ester (48): To a cooled (−70° C.) solution of 2-R-(4-benzyloxy-benzyl)-6-oxo-piperidine-1-carboxylic acid tert-butyl ester, 47, (12.0 g, 30.3 mmol), in THF (240 mL) and ethylene glycol dimethyl ether (240 mL) is added sodium bis(trimethylsilyl)-amide (33 mL, 1M solution in THF, 33 mmol). The resulting solution is warmed to 0° C. for thirty minutes and then cooled to −70° C. and 4-fluorobenzyl bromide (5.2 g, 27.5 mmol) is added. The resulting solution is stirred at −70° C. for forty minutes and then quenched with saturated aqueous ammonium chloride (200 mL). The organic solvents are removed under reduced pressure and the remaining aqueous layer is extracted with ethyl acetate (1000 mL). The organic layer is separated and washed with water (200 mL) and saturated aqueous sodium chloride (200 mL). The organics are dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude product is purified over silica to afford 11.5 g (38%) of the title compound as a colorless solid. 1H NMR (CDCl3 300 MHz) δ 1.35-1.93 (m, 4H), 1.63 (s, 9H), 2.35-3.10 (m, 4H), 3.25-3.35 (m, 1H), 4.25-4.35 (m, 1H), 5.08 (s, 2H), 6.85-7.50 (m, 13H).
  • Preparation of 2-R-benzyl-6-(4-benzyloxy-phenyl)-5-R-tert-butoxy-carbonylamino-hexanoic acid (49): To a cooled (−3° C.) solution of 6-R-(4-benzyloxy-benzyl)-3-R-(4-fluoro-benzyl)-2-oxo-piperidine-1-carboxylic acid tert-butyl ester, 48, (11.5 g, 22.9 mmol), in THF (150 mL) is slowly added lithium hydroxide monohydrate (3.7 g, 88 mmol) so as to maintain the reaction temperature between −3° C. and +3° C. The resulting reaction mixture is stirred at 0° C. for five minutes and then 30% aqueous hydrogen peroxide solution (12 mL) is added over five minutes. The resulting solution was stirred at room temperature for one hour and then allowed to stir for eighteen hours. The organics solvent was removed under reduced pressure and the remaining residue partitioned between methylene chloride (1000 mL) and water (400 mL). Potassium hydrogen sulfate (200 mL, 1 M solution), was then added and the organics separated and washed with 10% aqueous sodium hydrogen sulfate (2×500 mL), water (500 mL) and saturated aqueous sodium chloride (500 mL). The organics are separated, dried over anhydrous magnesium sulfate filtered, and concentrated under reduced pressure to afford 10.8 g (91%) of the title compound as a colorless solid. 1H NMR (DMSO 300 MHz) δ 1.10-1.75 (m, 3H), 1.37 (s, 9H), 2.42-2.90 (m, 5H), 3.30-3.70 (m, 2H), 5.08 (s, 2H), 6.68 (d, 1H), 6.90-7.55 (m, 13H). 13C NMR (DMSO 75 MHz) ppm 28.65, 28.95, 32.51, 37.68, 47.27, 52.12, 69.84, 77.96, 128.29, 128.42, 129.09, 130.73, 131.17, 131.28, 132.13, 136.40, 137.98, 156.04, 157.36, 159.91, 163.12, 176.84. MS (ESI) m/z 522 (M+H+)
  • Preparation of [1-S-(4-benzyloxy-benzyl)-5-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-4-R-(4-fluoro-benzyl)-5-oxo-pentyl]-carbamic acid tert-butyl ester (50): To a solution of 6-(4-benzyloxy-phenyl)-5-S-tert-butoxycarbonylamino-2-R-(4-fluoro-benzyl)-hexanoic acid, 49, (110 mg, 0.21 mmol), 4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidine, 18, (50 mg, 0.20 mmol), 1-hydroxybenzotriazole (54 mg, 0.40 mmol), 4-methylmorpholine (88 μL, 0.80 mmol) in N,N-dimethylformamide (7 mL) is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (50 mg, 0.26 mmol). The reaction mixture is stirred overnight and then aqueous ammonium chloride is added. The reaction is extracted with ethyl acetate, and the organics are separated dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by preparative HPLC to afford 111 mg (74% yield) of the desired compound. MS (ESI) m/z 752, (M+H+).
  • Preparation of 5-S-amino-6-(4-benzyloxy-phenyl)-1-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-R-(4-fluoro-benzyl)-hexan-1-one (51): A ready-to-use solution of trifluoroacetic acid:methylene chloride:water (1:1:0.1, 6 mL) is added to [1-S-(4-benzyloxy-benzyl)-5-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-4-R-(4-fluoro-benzyl)-5-oxo-pentyl]-carbamic acid tert-butyl ester (100 mg, 0.13 mmol), and the reaction mixture is stirred for 0.5-1.0 hour. The mixture is concentrated under reduced pressure and then partitioned between ethyl acetate and aqueous sodium bicarbonate. The organic layer is separated and concentrated under reduced pressure. The crude material is used without further purification.
  • Preparation of N-[1-S-(4-benzyloxy-benzyl)-5-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-4-R-(4-fluoro-benzyl)-5-oxo-pentyl]-acetamide (52): To a chilled (0° C.) solution of the 5-S-amino-6-(4-benzyloxy-phenyl)-1-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-R-(4-fluoro-benzyl)-hexan-1-one, 51, and triethylamine (54 μL, 0.39 mmol) in methanol (5 mL) is added acetic anhydride (39 μL, 0.41 mmol) dropwise. The mixture is stirred for one hour at room temperature. The excess triethylamine, acetic anhydride and solvent are removed under reduced pressure. The crude product is used directly in the next step. MS (ESI) m/z 694, (M+H+).
  • Preparation of N-[5-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-4-R-(4-fluoro-benzyl)-1-S-(4-hydroxy-benzyl)-5-oxo-pentyl]-acetamide (53): To a solution of N-[1-S-(4-benzyloxy-benzyl)-5-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-4-R-(4-fluoro-benzyl)-5-oxo-pentyl]-acetamide, 52, (100 mg) in ethanol (4 mL) was added 10% palladium on carbon (120 mg) under argon. The mixture is purged with a hydrogen and then stirred for two hours under a hydrogen atmosphere at atmospheric pressure. The reaction mixture was then filtered through a short pad of Celite and the filtrate is concentrated under reduced pressure. The crude product is purified by preparative HPLC to give 170 mg of the desired compound as the trifluoroacetic acid salt. MS (ESI) m/z 604, (M+H+).
  • The second aspect of Category II relates to compounds having the formula:
    Figure US20050171158A1-20050804-C00087
    wherein either R3a and R3b or R4a and R4b are taken together to form a carbonyl unit. The following are non-limiting examples which particularly point out examples of compounds comprising the second aspect of Category II analogs.
  • Compounds wherein R3a and R3b are each hydrogen, j is equal to 1; k is equal to 0 pounds having the formula:
    Figure US20050171158A1-20050804-C00088
  • wherein R, R2 and Q are defined herein below in Table V.
    TABLE V
    No. R R2 W1 Q
    261 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CO2H
    262 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONH2
    263 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONHCH3
    264 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONH(CH3)2
    265 4-chlorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONHSO2CH3
    266 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl —CO2H
    267 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl —CONH2
    268 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl —CONHCH3
    269 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl —CONH(CH3)2
    270 4-chlorophenyl 2H-tetrazol-5-yl cyclohexyl —CONHSO2CH3
    271 4-chlorophenyl imdazol-1-yl cyclohexyl —CO2H
    272 4-chlorophenyl imdazol-1-yl cyclohexyl —CONH2
    273 4-chlorophenyl imdazol-1-yl cyclohexyl —CONHCH3
    274 4-chlorophenyl imdazol-1-yl cyclohexyl —CONH(CH3)2
    275 4-chlorophenyl imdazol-1-yl cyclohexyl —CONHSO2CH3
    276 4-fluorophenyl [1,2,4]triazol-1-yl cyclohexyl —CO2H
    277 4-fluorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONH2
    278 4-fluorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONHCH3
    279 4-fluorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONH(CH3)2
    280 4-fluorophenyl [1,2,4]triazol-1-yl cyclohexyl —CONHSO2CH3
    281 4-fluorophenyl 2H-tetrazol-5-yl cyclohexyl —CO2H
    282 4-fluorophenyl 2H-tetrazol-5-yl cyclohexyl —CONH2
    283 4-fluorophenyl 2H-tetrazol-5-yl cyclohexyl —CONHCH3
    284 4-fluorophenyl 2H-tetrazol-5-yl cyclohexyl —CONH(CH3)2
    285 4-fluorophenyl 2H-tetrazol-5-yl cyclohexyl —CONHSO2CH3
    286 4-fluorophenyl imdazol-1-yl cyclohexyl —CO2H
    287 4-fluorophenyl imdazol-1-yl cyclohexyl —CONH2
    288 4-fluorophenyl imdazol-1-yl cyclohexyl —CONHCH3
    289 4-fluorophenyl imdazol-1-yl cyclohexyl —CONH(CH3)2
    290 4-fluorophenyl imdazol-1-yl cyclohexyl —CONHSO2CH3
    291 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CO2H
    292 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CONH2
    293 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CONHCH3
    294 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CONH(CH3)2
    295 4-chlorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CONHSO2CH3
    296 4-chlorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CO2H
    297 4-chlorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CONH2
    298 4-chlorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CONHCH3
    299 4-chlorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CONH(CH3)2
    300 4-chlorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CONHSO2CH3
    301 4-chlorophenyl imdazol-1-yl piperidin-4-yl —CO2H
    302 4-chlorophenyl imdazol-1-yl piperidin-4-yl —CONH2
    303 4-chlorophenyl imdazol-1-yl piperidin-4-yl —CONHCH3
    304 4-chlorophenyl imdazol-1-yl piperidin-4-yl —CONH(CH3)2
    305 4-chlorophenyl imdazol-1-yl piperidin-4-yl —CONHSO2CH3
    306 4-fluorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CO2H
    307 4-fluorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CONH2
    308 4-fluorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CONHCH3
    309 4-fluorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CONH(CH3)2
    310 4-fluorophenyl [1,2,4]triazol-1-yl piperidin-4-yl —CONHSO2CH3
    311 4-fluorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CO2H
    312 4-fluorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CONH2
    313 4-fluorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CONHCH3
    314 4-fluorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CONH(CH3)2
    315 4-fluorophenyl 2H-tetrazol-5-yl piperidin-4-yl —CONHSO2CH3
    316 4-fluorophenyl imdazol-1-yl piperidin-4-yl —CO2H
    317 4-fluorophenyl imdazol-1-yl piperidin-4-yl —CONH2
    318 4-fluorophenyl imdazol-1-yl piperidin-4-yl —CONHCH3
    319 4-fluorophenyl imdazol-1-yl piperidin-4-yl —CONH(CH3)2
    320 4-fluorophenyl imdazol-1-yl piperidin-4-yl —CONHSO2CH3
  • Figure US20050171158A1-20050804-C00089
    • Reagents and Conditions: (a) Na, MeOH; Reflux 2 hr.
  • Figure US20050171158A1-20050804-C00090
    • Reagents and Conditions: (b) lypozyme, benzyl alcohol; 40° C. 18 hr.
  • Figure US20050171158A1-20050804-C00091
    • Reagents and Conditions: (c) 5% Pd/C, hexane/toluene; rt.
  • Figure US20050171158A1-20050804-C00092
    • Reagents and Conditions: (d) HOBt, NMM, EDCI; rt 18 hr.
  • Figure US20050171158A1-20050804-C00093
    • Reagents and Conditions: (e) LiOH, THF/H2O; rt 18 hr.
  • Figure US20050171158A1-20050804-C00094
    • Reagents and Conditions: (f) ethane 1,1-diamine, EDCI, NMM, HOBt; rt 12 hr. EXAMPLE 5 N-(1-Aminoethyl)-3-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl-2-(4-fluorobenzyl)-3-oxo-propionamide (59)
  • Preparation of 2-(4-fluorobenzyl)-malonic acid dimethyl ester (54): To a solution of anhydrous methanol (250 mL) is added sodium metal (2.875 g, 0.125 mol) piecewise until the evolution of gas has deceased. Dimethyl malonate (16.5 g, 0.125 mol) is added dropwise and the mixture is stirred for 30 minutes. 4-Fluoro benzyl bromide (23.8 g, 0.126 mol) is added dropwise, and the reaction is refluxed for 2 hour. The majority of the solvent is removed under vacuum, and aqueous HCl is added. The solution is extracted with CHCl3, dried, and the solvent removed in vacuo. Distillation of the crude material under reduced pressure provides the desired compound which is used without further purification.
  • Preparation of 2-(4-fluorobenxyl)-malonic acid benzyl ester methyl ester (55): Lipozyme (4.0 g) is added to a solution of 2-(4-fluorobenzyl)-malonic acid dimethyl ester, 54, (1.0, 4.7 mmol) and benzyl alcohol (2.9 mL) in hexane (30 mL). The suspension is shaken at 40° C. and 200 rpm. After 18 hours the reaction is filtered, the solvent is removed in vacuo and the crude product purified over silica to afford the desired product which is used without further purification.
  • Preparation of 2-(4-fluorobenzyl)-malonic acid monomethyl ester (56): 5% Pd/C (64 mg) is added to a solution of 2-(4-fluorobenxyl)-malonic acid benzyl ester methyl ester, 55, (126 mg, 0.4 mmol) in 1:1 hexane/toluene (20 mL). Hydrogenation is carried out at RT until starting material is consumed. The catalyst is removed by filtration, and the solvent removed in vacuo to afford the desired product which is used without further purification.
  • Preparation of 3-(4-cylcohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-(4-fluorobenzyl)-3-oxo-propionic acid methyl ester (57): To a solution of 2-(4-fluoro-benzyl)-malonic acid monomethyl ester, 56, (47.5 mg, 0.21 mmol), 4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidine, 18, (50 mg, 0.20 mmol), 1-hydroxybenzotriazole (54 mg, 0.40 mmol), 4-methylmorpholine (88 □l, 0.80 mmol) in N,N-dimethylformamide (7 mL) is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (50 mg, 0.26 mmol). The reaction mixture is stirred overnight and then aqueous ammonium chloride is added. The reaction is extracted with ethyl acetate, and the organics are separated dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product is purified by preparative HPLC to afford the desired compound.
  • Preparation of 3-(4-cylcohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-(4-fluorobenzyl)-3-oxo-propionic acid (58): To a solution of 3-(4-cylcohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-(4-fluorobenzyl)-3-oxo-propionic acid methyl ester, 57, (456 mg, 1 mmol) in THF/H2O (2:1) at RT is added LiOH (1.5 equiv.). The reaction is stirred at RT until the starting material is consumed. The solvent is removed in vacuo, and the residue is purified by reverse phase HPLC to provide the desired product.
  • Preparation of N-(1-Aminoethyl)-3-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl-2-(4-fluorobenzyl)-3-oxo-propionamide (59): To a mixture of 3-(4-cylcohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-(4-fluorobenzyl)-3-oxo-propionic acid, 58, (442 mg, 1 mmol) and ethane 1,1-diamine (60 mg, 1 mmol) is added 1-hydroxy-benzotriazole (48.5 mg, 1.1 mmol), 4-methylmorpholine (176 μL, 1.6 mmol) in N,N-dimethylformamide (10 mL). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (200 mg, 1.04 mmol) is then added and the reaction is stirred at room temperature for 12 hours then poured into a mixture of water/CH2Cl2. The organic layer is separated, dried and concentrated to afford a crude product which is purified by reverse phase HPLC to provide the desired product.
  • For Category II compounds, other suitable R2 units include —NHC(═NH)NH2, —NHC(O)NH2, —NHC(═NCH3)NH2, or —NHC(═NCN)NHNO2. Other suitable Q units include quinolinyl, isoquinolinyl, indolyl, tetrahydroquinolinyl, tetrahydrodisoquinolinyl, imidazolyl, and triazolyl. For the first aspect of Category II the index j can be 0, 1, or 2.
    • Formulations
  • The present invention also relates to compositions or formulations which comprise the melanocortin receptor ligands according to the present invention. In general, the compositions of the present invention comprise:
      • a) an effective amount of one or more melanocortin receptor ligands according to the present invention; and
      • b) one or more pharmaceutically acceptable excipients.
  • The compositions of this invention are typically provided in unit dosage form. For the purposes of the present invention the term “unit dosage form” is defined herein as comprising an effective amount of one or more melanocortin receptor ligands. The compositions of the present invention contain in one embodiment from about 1 mg to about 750 mg of one or more melanocortin receptor ligands, while in other embodiments the compositions comprise from about 3 mg to about 500 mg, or from about 5 mg to about 300 mg respectively.
  • For the purposes of the present invention the term “excipient” and “carrier” are used interchangeably throughout the description of the present invention and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
  • The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the fact the compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.
  • Non-limiting examples of substances which can serve as pharmaceutically-acceptable excipients or components thereof are sugars, inter alia, lactose, glucose and sucrose, sorbitol, mannitol; starches, inter alia, corn starch and potato starch; cellulose and its derivatives, inter alia, sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; vegetable oils, propylene glycol, glycerin, and polyethylene glycol; agar; alginic acid; wetting agents and lubricants, inter alia, sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and buffers.
  • Standard pharmaceutical formulation techniques are disclosed in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., latest edition and Peptide and Protein Drug Delivery, Marcel Dekker, NY, 1991. Dosage forms useful for making the compositions of the present invention or which are compatible with the methods of use as described herein below are described in the following references, all incorporated by reference herein: Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms 2d Edition (1976).
  • The present invention further relates to forms of the present compounds, which under normal human or higher mammalian physiological conditions, release the compounds described herein. One iteration of this aspect includes the pharmaceutically acceptable salts of the analogs described herein. The formulator, for the purposes of compatibility with delivery mode, excipients, and the like, can select one salt form of the present analogs over another since the compounds themselves are the active species which mitigate the disease processes described herein.
  • Related to this aspect are the various precursor or “pro-drug” forms of the analogs of the present invention. It may be desirable to formulate the compounds of the present invention as a chemical species which itself is not a melanocortin receptor ligand as described herein, but instead are forms of the present analogs which when delivered to the body of a human or higher mammal will undergo a chemical reaction catalyzed by the normal function of the body, inter alia, enzymes present in the stomach, blood serum, said chemical reaction releasing the parent analog. Or alternatively, said “pro-drug” form may cross the blood/brain barrier before undergoing a change which releases the melanocortin receptor ligand in its active form. The term “pro-drug” relates to these species which are converted in vivo to the active pharmaceutical.
    • Method of Use
  • The present invention also relates to a method for controlling one or more melanocortin receptor, MC-3 or MC-4, mediated or melanocortin receptor modulated mammalian diseases or conditions, said method comprising the step of administering to a human or higher mammal an effective amount of a composition comprising one or more of the melanocortin receptor ligands according to the present invention.
  • Because the melanocortin receptor ligands of the present invention can be delivered in a manner wherein more than one site of control can be achieved, more than one disease state can be modulated at the same time. Non-limiting examples of diseases which are affected by an antagonist or agonist which stimulates the MC-3 or MC-4 receptor, obesity and other body weight disorders, inter alia, anorexia and cachexia. Utilizing the melanocortin receptor ligands of the present invention will therefore affect a variety of diseases, disease states, conditions, or syndromes resulting from body weight disorders, inter alia, insulin resistance, glucose intolerance, Type-2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, cancer (e.g., endometrial, cervical, ovarian, breast, prostate, gallbladder, colon), menstrual irregularities, hirsutism, infertility, gallbladder disease, restrictive lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease.
  • MC-3 and MC-4 receptor ligands are also effective in treating disorders relating to behavior, memory (including learning), cardiovascular function, inflammation, sepsis, cardiogenic and hypovolemic shock, sexual dysfunction, penile erection, muscle atrophy, nerve growth and repair, intrauterine fetal growth, and the like.
  • Although the melanocortin receptor ligands of the present invention are discrete chemical entities, the method of delivery or the method of use may be coupled with other suitable drug delivery systems. For example, a drug delivery technique useful for the compounds of the present invention is the conjugation of the compound to an active molecule capable of being transported through a biological barrier (see e.g. Zlokovic, B. V., Pharmaceutical Research, Vol. 12, pp. 1395-1406 (1995)). A specific example constitutes the coupling of the compound of the invention to fragments of insulin to achieve transport across the blood brain barrier (Fukuta, M., et al. Pharmaceutical Res., Vol. 11, pp. 1681-1688 (1994)). For general reviews of technologies for drug delivery suitable for the compounds of the invention see Zlokovic, B. V., Pharmaceutical Res., Vol. 12, pp. 1395-1406 (1995) and Pardridge, W M, Pharmacol. Toxicol., Vol. 71, pp. 3-10 (1992).
    • Procedures
  • The compounds of the present invention can be evaluated for efficacy, for example, measurements of cytokine inhibition constants, Ki, and IC50 values can be obtained by any method chosen by the formulator.
  • Non-limiting examples of suitable assays include:
      • i) UV-visible substrate enzyme assay as described by L. Al Reiter, Int. J. Peptide Protein Res., 43, 87-96 (1994).
      • ii) Fluorescent substrate enzyme assay as described by Thomberry et al., Nature, 356, 768-774 (1992).
      • iii) PBMC Cell assay as described in U.S. Pat. No. 6,204,261 B1 Batchelor et al., issued Mar. 20, 2001.
      • iv) accumulation of second messenger elements such as cAMP described by Chen et al., Anal Biochem. 226, 349-54, (1995).
  • Each of the above citations is included herein by reference.
  • Functional activity (in vitro pre-screening) can be evaluated using various methods known in the art. For example, measurement of the second messenger, cAMP, as described in citation (iv) above, evaluation by Cytosensor Microphysiometer techniques (Boyfield et al. 1996), or by using the compounds of the invention alone, or in combination with natural or synthetic MSH-peptides.
  • The compounds of the present invention will interact preferentially (i.e., selectively) to MC-4 and/or MC-3, relative to the other melanocortin receptors. Selectivity is particularly important when the compounds are administered to humans or other animals, to minimize the number of side effects associated with their administration. MC-3/MC-4 selectivity of a compound is defined herein as the ratio of the EC50 of the compound for an MC-1 receptor (“EC50-MC-1”) over the EC50 of the compound for the MC-3 (EC50-MC-3)/MC-4 (EC50-MC-4) receptor, the EC50 values being measured as described above. The formulas are as follows:
    MC-3 selectivity=[EC 50-MC-1]/[EC 50-MC-3]
    MC-4 selectivity=[EC 50-MC-1]/[EC 50-MC-4]
  • For the purposes of the present invention a receptor ligand (analog) is defined herein as being “selective for the MC-3 receptor” when the above-mentioned ratio “MC-3-selectivity” is at least about 10. In other treatments, methods, or compositions this value is at least about 100, while for yet other embodiments of the present invention the selectivity is at least about 500.
  • A compound is defined herein as being “selective for the MC-4 receptor” when the above-mentioned ratio “MC-3-selectivity” is at least about 10. In other treatments, methods, or compositions this value is at least about 100, while for yet other embodiments of the present invention the selectivity is at least about 500.
  • While particular aspects of the present invention and embodiments thereof have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims (20)

1. A compound, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:
Figure US20050171158A1-20050804-C00095
wherein R is a substituted or unsubstituted aromatic carbocyclic ring Q is a substituted or unsubstituted unit selected from:
i) C1-C22 linear or branched alkyl;
ii) C2-C22 linear or branched alkenyl;
iii) C2-C22 linear or branched alkynyl; and
iv) C6-C14 aromatic carbocyclic rings;
R2 is a C1-C7 non-aromatic heterocyclic ring or C3-C13 aromatic heterocyclic ring.
2. A compound according to claim 1 wherein R is substituted or unsubstituted phenyl.
3. A compound according to claim 2 wherein R is selected from the group consisting of phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, and 4-methylphenyl.
4. A compound according to claim 3 wherein R is 4-chlorophenyl.
5. A compound according to claim 1 wherein Q is substituted or unsubstituted C1-C22 linear or branched alkyl.
6. A compound according to claim 5 wherein Q is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, and tert-butyl.
7. A compound according to claim 1 wherein Q is a substituted or unsubstituted C6-C14 aromatic carbocyclic ring.
8. A compound according to claim 7 wherein Q is phenyl, 4-methylphenyl, or 4-hydroxyphenyl.
9. A compound according to claim 7 wherein Q is naphthalen-1-yl or naphthalen-2-yl.
10. A compound according to claim 1 wherein R2 is selected from the group consisting of:
i) thiazolyl, 2-methylthiazolyl, 4-mentylthiazolyl, 5-methylthiazolyl having the formula:
Figure US20050171158A1-20050804-C00096
ii) 1,3,4-thiadiazolyl, 2-methyl-1,3,4-thiadiazolyl having the formula:
Figure US20050171158A1-20050804-C00097
iii) 1,2,5-thiadiazolyl, 3-methyl-1,2,5-thiadiazolyl having the formula:
Figure US20050171158A1-20050804-C00098
iv) oxazolyl, 2-methyloxazolyl, 4-methyloxazolyl, 5-methyloxazolyl having the formula:
Figure US20050171158A1-20050804-C00099
v) imidazolyl, 2-methylimidazolyl, 5-methylimidazolyl having the formula:
Figure US20050171158A1-20050804-C00100
vi) 5-methyl-1,2,4-oxadiazolyl, 2-methyl-1,3,4-oxadiazolyl, 5-amino-1,2,4-oxadiazolyl, having the formula:
Figure US20050171158A1-20050804-C00101
vii) 1,2-dihydro[1,2,4]triazol-3-one-1-yl, 2-methyl-1,2-dihydro[1,2,4]triazol-3-one-5-yl, having the formula:
Figure US20050171158A1-20050804-C00102
viii) oxazolidin-2-one-3-yl; 4,4-dimethyloxazolidin-2-one-3-yl; imidazolidin-2-one-1-yl; 1-methylimidazolidin-2-one-1-yl, having the formula:
Figure US20050171158A1-20050804-C00103
ix) 2-methyl-1,3,4-oxadiazolyl, 2-amino-1,3,4-oxadiazolyl, 2-(N,N-dimethylamino)-1,3,4-oxadiazolyl, having the formula:
Figure US20050171158A1-20050804-C00104
11. A compound according to claim 1 wherein R2 is selected from the group consisting of:
i) triazoles having the formula:
Figure US20050171158A1-20050804-C00105
ii) tetrazole having the formula:
Figure US20050171158A1-20050804-C00106
12. A compound according to claim 1 wherein R2 is [1,2,4]triazol-1-yl, 2H-tetrazol-5-yl, or imidazol-1-yl.
13. A compound, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:
Figure US20050171158A1-20050804-C00107
wherein R is a substituted or unsubstituted aromatic carbocyclic ring
Q is a substituted or unsubstituted unit selected from:
i) C1-C22 linear or branched alkyl;
ii) C2-C22 linear or branched alkenyl;
iii) C2-C22 linear or branched alkynyl; and
iv) C6-C14 aromatic carbocyclic rings;
R2 is selected from —(CH2)2NH2, —(CH2)2NHC(═NH)NH2, —(CH2)2NHC(O)NH2, —(CH2)2NHC(═NCH3)NH2, and —(CH2)2NHC(═NCN)NHNO2.
14. A compound according to claim 13 wherein R is substituted or unsubstituted phenyl.
15. A compound according to claim 14 wherein R is selected from the group consisting of phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, and 4-methylphenyl.
16. A compound according to claim 15 wherein R is 4-chlorophenyl.
17. A compound according to claim 13 wherein Q is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, and tert-butyl.
18. A compound according to claim 13 wherein Q is a phenyl, 4-methylphenyl, or 4-hydroxyphenyl.
19. A compound and the salts thereof selected from the group consisting of:
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-ethanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-propanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-isopropanesulfonamide;
N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide;
N-[1-(R)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide;
N-[1-(S)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide; and
N-[1-(S)-(4-fluorobenzyl)-2-(4-cyclohexyl-4-imidazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-trifluoromethanesulfonamide.
20. A composition comprising:
A) an effective amount of one or more melanocortin receptor ligands, said ligands having the formula:
Figure US20050171158A1-20050804-C00108
wherein R is a substituted or unsubstituted aromatic carbocyclic ring
Q is a substituted or unsubstituted unit selected from:
i) C1-C22 linear or branched alkyl;
ii) C2-C22 linear or branched alkenyl;
iii) C2-C22 linear or branched alkynyl; and
iv) C6-C22 aromatic carbocyclic rings;
R2 is a C1-C7 non-aromatic heterocyclic ring or C3-C13 aromatic heterocyclic ring; and
B) one or more pharmaceutically acceptable excipients.
US11/092,100 2002-04-30 2005-03-29 Melanocortin receptor ligands Abandoned US20050171158A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/092,100 US20050171158A1 (en) 2002-04-30 2005-03-29 Melanocortin receptor ligands

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37658502P 2002-04-30 2002-04-30
US10/410,775 US7026335B2 (en) 2002-04-30 2003-04-09 Melanocortin receptor ligands
US11/092,100 US20050171158A1 (en) 2002-04-30 2005-03-29 Melanocortin receptor ligands

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/410,775 Continuation US7026335B2 (en) 2002-04-30 2003-04-09 Melanocortin receptor ligands

Publications (1)

Publication Number Publication Date
US20050171158A1 true US20050171158A1 (en) 2005-08-04

Family

ID=29401370

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/410,775 Expired - Fee Related US7026335B2 (en) 2002-04-30 2003-04-09 Melanocortin receptor ligands
US11/092,100 Abandoned US20050171158A1 (en) 2002-04-30 2005-03-29 Melanocortin receptor ligands

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/410,775 Expired - Fee Related US7026335B2 (en) 2002-04-30 2003-04-09 Melanocortin receptor ligands

Country Status (20)

Country Link
US (2) US7026335B2 (en)
EP (1) EP1499588A1 (en)
JP (1) JP2005525412A (en)
KR (1) KR20040104672A (en)
CN (1) CN1656070A (en)
AR (1) AR039779A1 (en)
AU (1) AU2003230923A1 (en)
BR (1) BR0309744A (en)
CA (1) CA2483787A1 (en)
IL (1) IL164766A0 (en)
MA (1) MA27306A1 (en)
MX (1) MXPA04010761A (en)
NO (1) NO20045136L (en)
NZ (1) NZ536099A (en)
PE (1) PE20040085A1 (en)
PL (1) PL373695A1 (en)
RU (1) RU2004134718A (en)
TW (1) TW200409639A (en)
WO (1) WO2003093234A1 (en)
ZA (1) ZA200408529B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
WO2004078717A1 (en) 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
JP2005170803A (en) * 2003-12-08 2005-06-30 Daicel Chem Ind Ltd Novel monomethyl malonate derivatives and their production
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
KR20080048502A (en) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2625877A1 (en) 2005-10-18 2007-04-26 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
TW200940523A (en) * 2008-03-17 2009-10-01 Gruenenthal Gmbh Substituted sulfonamide derivatives
AR071193A1 (en) * 2008-04-08 2010-06-02 Gruenenthal Chemie SUBSTITUTED DERIVATIVES OF SULFONAMIDE AND ITS EMPLOYMENT IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY B1R RECEPTORS.
WO2010056717A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NEW PROLYLCARBOXYPEPTIDASE INHIBITORS
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
CN111072551A (en) * 2019-12-30 2020-04-28 上海睿瓦科技有限公司 Method for preparing piperidine amine by catalytic hydrogenation one-step method

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5536716A (en) * 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5783582A (en) * 1994-07-20 1998-07-21 Merck & Co., Inc. Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
US5804578A (en) * 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
US5880125A (en) * 1996-03-21 1999-03-09 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US5936089A (en) * 1995-05-29 1999-08-10 Pfizer Inc Dipeptides which promote release of growth hormone
US5965565A (en) * 1996-12-12 1999-10-12 Merck & Co., Inc. Piperidines promote release of growth hormone
US6979691B2 (en) * 2001-03-02 2005-12-27 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK704488D0 (en) * 1988-12-19 1988-12-19 Novo Industri As NEW N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS
NZ258412A (en) 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5767118A (en) 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc Isoquinoline compound melanocortin receptor ligands and methods of using same
CA2329881C (en) 1998-05-11 2010-03-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
JP2002517444A (en) 1998-06-11 2002-06-18 メルク エンド カムパニー インコーポレーテッド Spiropiperidine derivatives as melanocortin receptor agonists
EP1187614A4 (en) 1999-06-04 2005-06-22 Merck & Co Inc SUBSTITUTED PIPERIDINES AS AGONISTS OF MELANOCORTIN-4 RECEPTOR
AU2001249281B2 (en) 2000-03-23 2005-01-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2403686C (en) 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
AU2001260548A1 (en) 2000-06-28 2002-01-08 Pfizer Products Inc. Melanocortin receptor ligands
CA2419310A1 (en) 2000-08-23 2002-02-28 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
EP1368339A1 (en) 2001-01-23 2003-12-10 Eli Lilly & Company Substituted piperidines/piperazines as melanocortin receptor agonists
JP2004523530A (en) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー Piperazine and piperidine derivatives as melanocortin receptor agonists
ES2272703T3 (en) 2001-02-28 2007-05-01 MERCK & CO., INC. PIPERIDINE DERIVATIVES ACILATED AS RECEIVER AGONISTS OF MELANOCORTINA-4.
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALOPEPTIDES
WO2003031410A1 (en) 2001-10-09 2003-04-17 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536716A (en) * 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5783582A (en) * 1994-07-20 1998-07-21 Merck & Co., Inc. Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
US5936089A (en) * 1995-05-29 1999-08-10 Pfizer Inc Dipeptides which promote release of growth hormone
US5880125A (en) * 1996-03-21 1999-03-09 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US5804578A (en) * 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
US5965565A (en) * 1996-12-12 1999-10-12 Merck & Co., Inc. Piperidines promote release of growth hormone
US6979691B2 (en) * 2001-03-02 2005-12-27 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
IL164766A0 (en) 2005-12-18
EP1499588A1 (en) 2005-01-26
KR20040104672A (en) 2004-12-10
US20030236230A1 (en) 2003-12-25
AU2003230923A1 (en) 2003-11-17
RU2004134718A (en) 2005-07-20
NZ536099A (en) 2006-09-29
CA2483787A1 (en) 2003-11-13
WO2003093234A1 (en) 2003-11-13
BR0309744A (en) 2005-02-09
US7026335B2 (en) 2006-04-11
AR039779A1 (en) 2005-03-02
TW200409639A (en) 2004-06-16
JP2005525412A (en) 2005-08-25
NO20045136L (en) 2005-01-24
ZA200408529B (en) 2005-07-07
PE20040085A1 (en) 2004-04-15
MA27306A1 (en) 2005-05-02
MXPA04010761A (en) 2005-03-07
CN1656070A (en) 2005-08-17
PL373695A1 (en) 2005-09-05

Similar Documents

Publication Publication Date Title
US7026335B2 (en) Melanocortin receptor ligands
US6911447B2 (en) Melanocortin receptor ligands
US20050239835A1 (en) Melanocortin receptor ligands
US7501524B2 (en) Derivatives of benzimidazole and imidazo-pyridine and their use as medicaments
US6294555B1 (en) 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US7132539B2 (en) Melanocortin receptor ligands
JP2010059213A (en) Muscarinic antagonist
US5140011A (en) Amino acid derivatives which have renin inhibiting activity
AU2002316531B2 (en) Substituted anilinic piperidines as MCH selective antagonists
JPWO1999055674A1 (en) 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, their preparation method, pharmaceutical compositions containing them, and intermediates for said compounds
KR19990044138A (en) Piperazino derivatives as neurokinin antagonists

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION